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1. INTRODUCTION {#ar23907-sec-0001}
===============

Purines and pyrimidines are nucleotides found in all cells, contributing to multiple processes, such as DNA/RNA construction, energy homeostasis, and cell signaling. In the peripheral and central nervous systems, purinergic signaling is a widespread mechanism for communication between neurons, glia, and vascular cells. Purines such as adenosine and adenosine triphosphate (ATP) can function as neurotransmitters, co‐transmitters, neuromodulators, and as signals in neuro--glial interactions (Burnstock, [2007](#ar23907-bib-0036){ref-type="ref"}; Boison, [2008a](#ar23907-bib-0029){ref-type="ref"}; Abbracchio et al., [2009](#ar23907-bib-0001){ref-type="ref"}; Housley et al., [2009](#ar23907-bib-0104){ref-type="ref"}; Koles et al., [2016](#ar23907-bib-0128){ref-type="ref"}). Accordingly, their functional impact on the nervous system is broad, including key roles in development, behavior, regeneration, plasticity, and pathology (Dale, [2008](#ar23907-bib-0061){ref-type="ref"}; Burnstock et al., [2011](#ar23907-bib-0038){ref-type="ref"}; Wei et al., [2011](#ar23907-bib-0207){ref-type="ref"}; Zimmermann, [2011](#ar23907-bib-0224){ref-type="ref"}; Del Puerto et al., [2013](#ar23907-bib-0065){ref-type="ref"}; Dias et al., [2013](#ar23907-bib-0066){ref-type="ref"}; Sebastiao and Ribeiro, [2015](#ar23907-bib-0179){ref-type="ref"}; Krugel, [2016](#ar23907-bib-0129){ref-type="ref"}; Pedata et al., [2016](#ar23907-bib-0160){ref-type="ref"}). In the brain, ATP and adenosine are released in an activity dependent manner from the presynaptic terminals of neurons by vesicle‐mediated exocytosis, postsynaptic membranes (dendrites), and axons (Fredholm et al., [2005](#ar23907-bib-0082){ref-type="ref"}; Wall and Dale, [2008](#ar23907-bib-0202){ref-type="ref"}; Abbracchio et al., [2009](#ar23907-bib-0001){ref-type="ref"}; Burnstock et al., [2011](#ar23907-bib-0038){ref-type="ref"}; Cunha, [2016](#ar23907-bib-0059){ref-type="ref"}). They may also be released by glia, especially astrocytes, *via* vesicular secretion, transport proteins, and membrane channels (Boison et al., [2010](#ar23907-bib-0033){ref-type="ref"}; Koles et al., [2016](#ar23907-bib-0128){ref-type="ref"}).

Their actions are mediated by purinergic receptors at pre‐, post‐, and nonsynaptic sites on neurons and glia. Adenosine is bound by members of the P1 receptor class (G‐protein‐coupled), and ATP by the larger P2 receptor family (P2X, ligand‐gated ion channel; P2Y, G‐protein‐coupled). The P1 and P2 receptor subtypes have varied levels of expression in neurons and glia of the cortex, hippocampus, cerebellum, striatum thalamus, brainstem, and spinal cord (Fields and Burnstock, [2006](#ar23907-bib-0075){ref-type="ref"}; Wei et al., [2011](#ar23907-bib-0207){ref-type="ref"}). For the P1 class, distributions of its four subtypes (A~1~, A~2A~, A~2B~, and A~3~) are generally distinct, with overlap in some brain regions, and may be colocalized in some cells. Likewise, the P2 receptors are widely expressed by neurons and glia in the brain, where the localization of specific subtypes can be distinct (Burnstock and Knight, [2004](#ar23907-bib-0037){ref-type="ref"}). Cell type‐specific transcriptome profiling has revealed that the expression of P1 and P2 receptors differs substantially among several major neuronal and glial subtypes (Cahoy et al., [2008](#ar23907-bib-0041){ref-type="ref"}; Zhang et al., [2014](#ar23907-bib-0221){ref-type="ref"}; Zeisel et al., [2015](#ar23907-bib-0217){ref-type="ref"}). In the auditory forebrain, transcriptome profiling indicated that several members of the P1 and P2 receptor classes are expressed in A1 and MG (Hackett et al., [2015](#ar23907-bib-0098){ref-type="ref"}). P1‐class expression was dominated by the A~1~ subtype, and P2‐class expression was highest for *P2rx4*, *P2rx7, P2ry1,* and *P2ry12* (Fig. [1](#ar23907-fig-0001){ref-type="fig"}). Additionally, transcript levels tended to increase or decrease during the maturational period studied (P7 through adult), especially between P7 and P14 (before and after hearing onset).

![Purinergic receptor transcript expression in the auditory forebrain (A1, MG) during postnatal development. For each gene, mean normalized read counts derived from RNA sequencing of A1 and MG are plotted at 4 postnatal ages (P7, P14, P21, adult). *Adora1* expression (top panels) is plotted separately from the P2 receptors (bottom panels) due to differences in scale. \**P* \< 0.05; \*\**P* \< 0.01. Data derived from Hackett et al. ([2015](#ar23907-bib-0098){ref-type="ref"}) database.](AR-301-1882-g001){#ar23907-fig-0001}

Studies in hippocampus and other brain regions reveal that adenosine can regulate synaptic transmission and plasticity through A~1~ and A~2a~ receptors located at pre‐ and postsynaptic sites on neurons and astrocytes (Ochiishi et al., [1999](#ar23907-bib-0153){ref-type="ref"}; Rebola et al., [2005](#ar23907-bib-0167){ref-type="ref"}; Sebastiao and Ribeiro, [2009](#ar23907-bib-0178){ref-type="ref"}; Sperlagh and Vizi, [2011](#ar23907-bib-0182){ref-type="ref"}; Ota et al., [2013](#ar23907-bib-0156){ref-type="ref"}; Chen et al., [2014](#ar23907-bib-0044){ref-type="ref"}; Sebastiao and Ribeiro, [2015](#ar23907-bib-0179){ref-type="ref"}). Importantly, neuromodulation by adenosine is not limited to glutamatergic transmission, but also other modulators (e.g., GABA, acetylcholine, BDNF, cannabinoids). The actions of adenosine *via* A~1~ and A~2a~ receptors are most often associated with inhibition and facilitation, respectively. The inhibitory effects of A~1~ receptors have primarily been observed at glutamatergic and cholinergic endings (hippocampus), but not GABAergic (Cunha and Ribeiro, [2000](#ar23907-bib-0060){ref-type="ref"}; Cristovao‐Ferreira et al., [2009](#ar23907-bib-0054){ref-type="ref"}). Instead, the A~1~ receptor appears to have indirect influence in particular interneuron subpopulations (Klausberger et al., [2005](#ar23907-bib-0124){ref-type="ref"}; Rombo et al., [2016](#ar23907-bib-0171){ref-type="ref"}), indicating cell‐type specificity in expression (Rivkees et al., [1995](#ar23907-bib-0170){ref-type="ref"}; Ochiishi et al., [1999](#ar23907-bib-0153){ref-type="ref"}) and mechanisms of action.

Consistent with the foregoing, recent studies of thalamocortical (TC) inputs to sensory cortex have revealed that adenosine functions as a negative regulator of glutamate release *via* activation of presynaptic A~1~ receptors (Fontanez and Porter, [2006](#ar23907-bib-0076){ref-type="ref"}; Bayazitov et al., [2007](#ar23907-bib-0020){ref-type="ref"}; Blundon et al., [2011](#ar23907-bib-0025){ref-type="ref"}; Chun et al., [2013](#ar23907-bib-0046){ref-type="ref"}; Ferrati et al., [2016](#ar23907-bib-0074){ref-type="ref"}). In the auditory forebrain, restriction of A~1~‐mediated adenosine signaling in medial geniculate (MG) neurons is sufficient to extend LTP, LTD, and tonotopic map plasticity in adult mice for months beyond the critical period (Blundon et al., [2011](#ar23907-bib-0025){ref-type="ref"}; Chun et al., [2013](#ar23907-bib-0046){ref-type="ref"}; Blundon et al., [2017](#ar23907-bib-0026){ref-type="ref"}). In contrast, restricting adenosine signaling in neurons of the primary auditory cortex (A1) does not contribute to these forms of plasticity, suggesting that the effects are confined to presynaptic TC projections. Thus, adenosine signaling through presynaptic A~1~ receptors on TC terminals appears to act as a gate that regulates glutamate release and plasticity at TC synapses in A1.

1.1. *Adora1* Expression by Neurons and Glia in the Auditory Forebrain {#ar23907-sec-0002}
----------------------------------------------------------------------

The focus of this study is the adenosine A~1~ receptor subtype (hereafter, A~1~R). The purpose was to advance understanding of the circuitry involved in A~1~R‐mediated adenosine signaling in the auditory forebrain by cells that express A~1~R mRNA transcripts (i.e., *Adora1*). Specific goals were to identify the neuronal and glial cell subtypes that express *Adora1*, and map their locations across laminae in primary auditory cortex (A1) and nuclear subdivisions of the medial geniculate body (MG), based on co‐expression with cell‐type specific markers.

Rationale for this study includes several observations. First, as indicated above, adenosine receptor expression is widespread, but can vary by brain region, cell class, and receptor subtype. The A~1~R subtype is the most highly expressed purinergic receptor in the auditory forebrain (Fig. [1](#ar23907-fig-0001){ref-type="fig"}), but its regional‐ and cell‐type‐specificity have not been profiled. Thus, the structural foundation for studies of A~1~R function has not been established.

Second, glia and neuron--glia interactions are involved in a vast array of brain functions that often involve adenosine signaling (Stevens et al., [2002](#ar23907-bib-0183){ref-type="ref"}; Fields and Burnstock, [2006](#ar23907-bib-0075){ref-type="ref"}; Boison, [2008a](#ar23907-bib-0029){ref-type="ref"}; Pelligrino et al., [2011](#ar23907-bib-0161){ref-type="ref"}; Lovatt et al., [2012](#ar23907-bib-0135){ref-type="ref"}; Del Puerto et al., [2013](#ar23907-bib-0065){ref-type="ref"}; Domercq et al., [2013](#ar23907-bib-0067){ref-type="ref"}; Bynoe et al., [2015](#ar23907-bib-0040){ref-type="ref"}; Coppi et al., [2015](#ar23907-bib-0051){ref-type="ref"}; Koles et al., [2016](#ar23907-bib-0128){ref-type="ref"}). Whether *Adora1* expression is restricted to specific neuronal and glial subpopulations or subdivisions of the auditory forebrain is unknown, but this knowledge is essential for the understanding and modeling of adenosine signaling in forebrain circuits.

Third, cell‐specific expression patterns have important implications for the design of experimental studies expecting to target *Adora1* (e.g., optogenetics, gene editing, pharmacology, behavior). Target specificity can significantly impact experimental outcomes and must be incorporated into experimental designs. For example, altering A~1~R expression at the mRNA or protein levels would be expected to produce different results if expression was common to all cells, as opposed to particular neuronal or glial subpopulations.

With these goals in mind, *in situ* hybridization (ISH) was used to profile the expression of *Adora1* transcripts in subclasses of neurons (glutamatergic, GABAergic) and glia (astrocytes, oligodendrocytes, microglia) in the auditory forebrain of adult mice. The results indicate that *Adora1* is widely expressed by neurons and glia in A1 and MG, but in a manner that varies by cell type and specific location. Thus, A~1~R‐mediated adenosine signaling would be expected to differentially impact subpopulations of neurons and glia in the auditory forebrain. Strategies to target *Adora1* in specific cell types can be developed from the data generated here.

2. MATERIALS AND METHODS {#ar23907-sec-0003}
========================

2.1. Tissue Acquisition {#ar23907-sec-0004}
-----------------------

All procedures were approved by the Animal Care and Use Committee at Vanderbilt University and followed the guidelines established by the National Institutes of Health for the care and use of laboratory animals. Brains collected from adult (8--10 weeks) C57BL/6J mice (Jackson Labs 000664), 8 of each sex. Animals were anesthetized with isoflurane in an isolation chamber until areflexive, and decapitated. Brains were immediately removed, blocked in the coronal plane, embedded in OCT compound (Tissue‐Tek, Torrance, CA), then flash frozen in liquid‐nitrogen‐cooled isopentane. Blocks containing 4 brains each (2 male and 2 female) were stored at −80°C. Blocks were sectioned coronally at 10 μm, and collected onto Superfrost Plus slides (Thermo Fisher Scientific, Waltham, MA), and stored at −80°C prior to histological assays.

2.2. Selection of Neuronal and Glial Markers {#ar23907-sec-0005}
--------------------------------------------

*Adora1* mRNA expression was studied in three subtypes of neurons and glia, based on co‐expression for cell‐specific markers (Table [1](#ar23907-tbl-0001){ref-type="table"}). Subpopulations of glutamatergic neurons were distinguished by expression or co‐expression of vesicular glutamate transporters 1 and 2 (*VGluT1, VGluT2*), which have a partially complementary distribution in the brain (Kaneko and Fujiyama, [2002](#ar23907-bib-0115){ref-type="ref"}; Fremeau et al., [2004](#ar23907-bib-0083){ref-type="ref"}). The expression of the vesicular GABA/glycine transporter (*VGAT*) is specific to GABAergic and glycinergic neurons (Chaudhry et al., [1998](#ar23907-bib-0043){ref-type="ref"}; Dumoulin et al., [1999](#ar23907-bib-0068){ref-type="ref"}). In a prior study, we mapped the spatial distributions of glutamatergic and GABAergic neurons in A1 and MG of adult and developing mice, based on expression of these markers (Hackett et al., [2016](#ar23907-bib-0099){ref-type="ref"}). *VGluT1* was preferentially expressed in A1, and *VGluT2* was co‐expressed with *VGluT1* in a small subset of those neurons. In MG, nearly all neurons expressed *VGluT2* or co‐expressed *VGluT1* and *VGluT2*. The expression of *VGAT* was restricted to neurons in A1, as GABAergic neurons are rare in the rodent MG. The *VGluT1, VGluT2,* and *VGAT* transcripts are highly specific to glutamatergic and GABAergic neuronal subpopulations in the forebrain (Zeisel et al., [2015](#ar23907-bib-0217){ref-type="ref"}).

###### 

Details of riboprobes for *Adora1* and markers of neuronal and glial subtypes targeted by *in situ* hybridization

  Cell type                          Protein                                    Gene                 Accession No.       Position
  ---------------------------------- ------------------------------------------ -------------------- ---------------- --------------
  Glutamatergic neuron               Vesicular glutamate transporter 1          *Slc17a7 (VGluT1)*   NM_182993.2        464--1,415
  Glutamatergic neuron               Vesicular glutamate transporter 2          *Slc17a6 (VGluT2)*   NM_080853.3       1986--2,998
  GABAergic neuron                   Vesicular GABA/glycine transporter         *Slc32a1 (VGAT)*     NM_009508.2        894--2037
  Astrocyte                          Aquaporin‐4                                *Aqp4*               NM_009700.2       1,646--2,644
                                                                                                                      
  Oligodendrocyte                    Myelin basic protein                       *MBP*                NM_001025259.2     648--2,107
                                                                                                                      
  Microglia                          Integrin subunit Alpha M                   *Itgam (Cd11b)*      NM_001082960.1     538--1,528
  General marker, positive control   Glyceraldehyde 3‐phosphate dehydrogenase   *Gapdh*              NM_008084.2         21--935
  All                                Adenosine A1 receptor                      *Adora1*             NM_001008533.2    4,018--4,999

Glial cell distributions have not been previously mapped in the auditory forebrain. Markers of each glial class were selected to achieve specific expression for that cell type, as well as the broadest expression across subpopulations of each class. For myelinating oligodendrocytes, myelin basic protein (*MBP*) was chosen for ubiquitous expression in myelinating oligodendrocytes in mature animals (Cahoy et al., [2008](#ar23907-bib-0041){ref-type="ref"}; Zeisel et al., [2015](#ar23907-bib-0217){ref-type="ref"}; Holt and Olsen, [2016](#ar23907-bib-0103){ref-type="ref"}). For astrocytes, aquaporin‐4 (*Aqp4*) was chosen over the more commonly used marker, glial fibrillary astrocytic protein (*GFAP*). *Aqp4* is highly specific to astrocytes (Venero et al., [1999](#ar23907-bib-0196){ref-type="ref"}; Badaut et al., [2002](#ar23907-bib-0011){ref-type="ref"}; Nicchia et al., [2004](#ar23907-bib-0151){ref-type="ref"}; Saadoun et al., [2005](#ar23907-bib-0172){ref-type="ref"}; Hsu et al., [2011](#ar23907-bib-0105){ref-type="ref"}; Aoyama et al., [2012](#ar23907-bib-0008){ref-type="ref"}; Papadopoulos and Verkman, [2013](#ar23907-bib-0157){ref-type="ref"}; Smith et al., [2014](#ar23907-bib-0181){ref-type="ref"}; Hubbard et al., [2015](#ar23907-bib-0107){ref-type="ref"}), and transcript expression levels are higher than *GFAP* for both major astrocyte subtypes (Cahoy et al., [2008](#ar23907-bib-0041){ref-type="ref"}; Zhang et al., [2014](#ar23907-bib-0221){ref-type="ref"}; Zeisel et al., [2015](#ar23907-bib-0217){ref-type="ref"}). Some evidence also suggests that *GFAP* is nominally expressed by some astrocyte subpopulations (Cahoy et al., [2008](#ar23907-bib-0041){ref-type="ref"}; Zeisel et al., [2015](#ar23907-bib-0217){ref-type="ref"}), and may be co‐expressed with chondroitin sulfate proteoglycan 4 (aka: *Cspg4*, *NG2*), a marker of oligodendrocyte precursor cells (Zhang et al., [2014](#ar23907-bib-0221){ref-type="ref"}; Alghamdi and Fern, [2015](#ar23907-bib-0003){ref-type="ref"}). For microglia, several specific markers of microglia are known (e.g., *Aif1, Cx3cr1*, *Hexb, Tlr4*), but the cell adhesion molecule, integrin alpha‐M (*Itgam*) (aka *Cd11b*) was chosen because it is more widely used as a marker and expressed by all subtypes (Zhang et al., [2014](#ar23907-bib-0221){ref-type="ref"}; Zeisel et al., [2015](#ar23907-bib-0217){ref-type="ref"}; Holt and Olsen, [2016](#ar23907-bib-0103){ref-type="ref"}).

2.3. *In situ* Hybridization (ISH) {#ar23907-sec-0006}
----------------------------------

Chromogenic and multiplex fluorescence assays were conducted using custom riboprobes designed and manufactured by Advanced Cell Diagnostics (ACD, Hayward, CA) (Wang et al., [2012](#ar23907-bib-0205){ref-type="ref"}) (Table [1](#ar23907-tbl-0001){ref-type="table"}). The vesicular transporter probes were previously used in studies of the mouse auditory forebrain (Hackett et al., [2016](#ar23907-bib-0099){ref-type="ref"}). These proprietary probes and assays (RNAscope) utilize a unique signal amplification and background suppression methodology that consistently yielded exceptionally high sensitivity and specificity with low background. Briefly, after a 30‐min protease permeabilization step, two independent probes (double Z probe) were hybridized for 2 hr to each target sequence (\~20 probe pairs per target molecule). The lower region of each probe is complementary to the target sequence, and the upper region is a 14‐base tail sequence. Together, the dual probe construct provides a 28‐base binding site for the preamplifiers, which were built up during a multistage amplification cycle. In the final steps, labeled probes containing the fluorescent or chromogen conjugates were bound to each of the 20 binding sites on each preamplifier. All incubation steps were performed at 40°C in a hybridization oven (HybEZ, ACD, Hayward CA) using the RNAscope Multiplex Fluorescent or Duplex Reagent kits, according to the manufacturer\'s instructions for fresh frozen brain tissue.

Single colorimetric ISH assays were conducted for *Adora1*, *VGluT1*, *VGluT2*, *VGAT*, *MBP*, *Aqp4*, and *Itgam* as a baseline reference for the locations of labeled cells. Then, duplex chromogenic assays paired each cell marker with the housekeeping gene, *Gapdh* (glyceraldehyde‐3‐phosphate dehydrogenase) as a positive control for a second riboprobe. Additional series of duplex chromogenic assays paired each cell marker with *Adora1*. In duplex assays, the red and blue--green substrates were fast‐red and fast‐green, respectively. As a negative control, sections were incubated in buffer solution that did not contain any riboprobes. These assays revealed no significant labeling in any channel. Multiplex fluorescence ISH (FISH) was performed in two separate series of sections. One combined all three neuronal markers with *Adora1* in separate channels (*VGluT1*, *VGluT2*, *VGAT*, *Adora1*), the other combined all three glial markers with *Adora1* (*MBP*, *Aqp4*, *Itgam, Adora1*). These assays were done to permit visualization of all genes in a single tissue section, and as a positive control for marker specificity.

All sections were counterstained to improve identification of brain areas and provide a focal point for cytoplasmic probe labeling. FISH‐reacted sections were counterstained with DAPI (30 sec), and chromogen‐reacted sections were counterstained with 50% hematoxylin (30 sec).

2.4. Antibody Selection and Immunohistochemistry (IHC) {#ar23907-sec-0007}
------------------------------------------------------

Four commercially available primary antibodies for A~1~R were evaluated for staining quality and consistency (Table [2](#ar23907-tbl-0002){ref-type="table"}). Antibody specificity was tested by incubating each antibody with a 10× concentration of the control protein provided by the manufacturer, when available. Negative controls, omitting the primary antibody, were used in the testing of all antibodies to assess nonspecific staining. Optimal primary antibody concentrations were determined from these tests, as listed in Table [2](#ar23907-tbl-0002){ref-type="table"}. The Protein‐Tech antibody consistently produced the strongest punctate signals in chromogenic assays of fresh frozen and fixed tissues. This A~1~R antibody was combined with the neuron‐specific marker, NeuN (*Fox3*) in dual fluorescence IHC assays as a marker of neuronal nuclei and somata, as detailed previously (Hackett et al., [2016](#ar23907-bib-0099){ref-type="ref"}). Secondary antibodies used for IHC and FIHC are listed in Table [2](#ar23907-tbl-0002){ref-type="table"}.

###### 

Primary and secondary antibodies used for IHC

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Antibody*            *Species*      *Supplier*        *Part Number*     *Dilution*                                                        *References*
  -------------------- ----------- ------------------- ------------------ ------------ -------------------------------------------------------------------------------------------------------------------------
  Primary antibodies                                                                   

  Adora1 A~1~R             rb         Protein‐Tech        55,026‐1‐AP        1:250                                      Burke et al., [2015](#ar23907-bib-0035){ref-type="ref"}

  Adora1 A~1~R             rb       Novus Biologicals      NB300‐549\        1:250       Kimura et al., [2003](#ar23907-bib-0123){ref-type="ref"}; Yamaguchi et al., [2014](#ar23907-bib-0215){ref-type="ref"}
                                                        RRID:AB_10002337               

  Adora1 A~1~R             gp         Alamone Labs          AAR‐006\         1:250      Garcia et al., [2013](#ar23907-bib-0088){ref-type="ref"}; Vindeirinho et al., [2013](#ar23907-bib-0198){ref-type="ref"}
                                                        RRID:AB_2039705                

  Adora1 A~1~R             rb         Aviva Systems        OABF01723\        1:250                                                                ‐‐‐
                                                        RRID: not listed               

  Fox3/NeuN                ms            Covance           SIG39860\         1:1000                                    Wimmer et al., [2010](#ar23907-bib-0211){ref-type="ref"}
                                                        RRID:AB_11220035               
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  -------------------------------------------------------------------------------------------------------
  Secondary antibodies                                                   
  ---------------------- ------- ------------- ----------------- ------- --------------------------------
                                                                         *Primary antibody combination*

  Anti‐rabbit IgG        G‐rb    Vector Labs   BA‐1000\          1:200   Adora1 A~1~R
                                               RRID:AB_2313606           

  Alexa 647              Ch‐rb   Lifetech      A21443\           1:400   Adora1 A~1~R
                                               RRID:AB_1500685           

  Alexa 750              Ch‐ms   Lifetech      A21037\           1:400   NeuN (Fox3)
                                               RRID:AB_1500644           
  -------------------------------------------------------------------------------------------------------

**Abbreviations:** ms, mouse; rb, rabbit; G/g, goat, Ch, chicken.

Single chromogenic IHC and dual fluorescence IHC (FIHC) assays were performed on slide‐mounted fresh‐frozen sections (10 μm) and fixed floating sections (40 μm). Sections were rinsed for 30 min in 0.01 M PBS‐Tx (phosphate buffered saline, 0.1% triton), followed by three changes of 0.01 M PBS for 10 min (standard rinse procedure). In FIHC assays, nonspecific labeling of myelin by fluorescent secondary antibodies was blocked by incubation in IT‐Fx (Life Tech) for 60 min at RT, followed by a standard rinse. In IHC and FIHC, sections were incubated for 5 min at RT in a single purified glyocoprotein blocking solution (Superblock, ScyTek Laboratories, Logan, UT), followed by a single rinse in PBS. Superblock reagent reduces nonspecific antibody binding, and was used in lieu of species‐specific sera or bovine serum albumin (Evans et al., [1996](#ar23907-bib-0072){ref-type="ref"}; Buttini et al., [2002](#ar23907-bib-0039){ref-type="ref"}; Turtzo et al., [2014](#ar23907-bib-0195){ref-type="ref"}). IHC sections were incubated for 48 hr in primary antibodies at 4°C, 2 hr in the biotinylated secondary antibody at RT, 1 hr in avidin--biotin solution (Vectastain ABC Kit, PK‐6100, Vector Laboratories, Burlingame, CA), then 5 min in the chromogen solution (ImmPACT VIP Kit, SK‐4605, Vector Laboratories). FIHC sections were then incubated for 48 hr in the primary antibodies at 4°C, then 2 hr in the secondary antibody cocktail (A~1~R + NeuN) at RT. Standard rinsing steps were performed between all incubations. All incubations and rinsing steps were performed on a laboratory shaker with constant agitation.

2.5. Image Acquisition and Analyses {#ar23907-sec-0008}
-----------------------------------

Bright‐field images of single colorimetric ISH and IHC tissue sections were obtained with a Nikon 80i microscope controlled by Neurolucida 10 software (MBF Bioscience). Fluorescence wide‐field images and image montages of FISH and FIHC sections were obtained with a Nikon 90i epiflourescence microscope and Hamamatsu Orca 4.0 CCD camera, controlled by Nikon Elements AR software using 20×, 40×, and 100× objectives. Exposure parameters for each color channel were maintained at the same levels across all samples to standardize signal intensity. Images were assembled into figures using Adobe Illustrator CS6 (Adobe Systems, Inc.). 40× and 100× images were created from z‐plane image stacks collapsed to two dimensions, using an Extended Depth of Focus plugin to the Nikon Elements software.

Identification of auditory cortex and medial geniculate was based on previously established architectonic criteria (Hackett et al., [2011a](#ar23907-bib-0096){ref-type="ref"}; Hackett et al., [2016](#ar23907-bib-0099){ref-type="ref"}), with reference to standard reference atlases (Franklin and Paxinos, [2007](#ar23907-bib-0077){ref-type="ref"}; Lein et al., [2007](#ar23907-bib-0133){ref-type="ref"}). Laminar density profiles of *Adora1* expression from auditory cortex (areas A1, AuD, AuV) were derived from images of colorimetric ISH sections converted to 8‐bit grayscale, then thresholded at 50% using ImageJ software (NIH, <http://nih.gov>). Raw grayscale intensity was measured using rectangular selection boxes (1,000 pixel width) from layer 1 (L1) just below the pial boundary through the white matter below L6. The average grayscale intensity value was averaged across 1,000 pixels of each row of pixels separately for A1. The resulting functions were smoothed using a 200‐point moving average.

Cell counts were performed manually from A1 and MG in 4 different brains using diffusion interference contrast (DIC) microscopy (40×, 100×) on chromogen‐reacted sections. For each marker, a cell was considered positively labeled (e.g., *Adora1* ^*+*^) if three or more labeled puncta were contained within the somatic cytoplasm (see Discussion for rationale). The average number of labeled and nonlabeled cells was tabulated for each layer of A1 and division of MG, along with their standard deviations. The X--Y locations of each cell were plotted on schematic diagrams of each brain region. The division between MGm and the suprageniculate nucleus (Sg) was approximated in figures, but their cell counts were combined, as definitive borders between the two divisions were ambiguous in these preparations, and because transcript distributions were typically uniform across the region. The difficulties in delineation of Sg in mouse have been noted previously, (Jones, [2007](#ar23907-bib-0114){ref-type="ref"}; Watson et al., [2012](#ar23907-bib-0206){ref-type="ref"}), and identification varies across studies (Cruikshank et al., [2001](#ar23907-bib-0057){ref-type="ref"}; Anderson et al., [2009](#ar23907-bib-0007){ref-type="ref"}; Lu et al., [2009](#ar23907-bib-0136){ref-type="ref"}; Anderson and Linden, [2011](#ar23907-bib-0006){ref-type="ref"}; Marquez‐Legorreta et al., [2016](#ar23907-bib-0139){ref-type="ref"}).

3. RESULTS {#ar23907-sec-0009}
==========

3.1. Regional and Local Distributions of *Adora1* mRNA {#ar23907-sec-0010}
------------------------------------------------------

*Adora1* mRNA expression was widespread in the adult mouse brain, but concentrations of *Adora1* ^*+*^ puncta varied by regional and subcellular location. Figure [2](#ar23907-fig-0002){ref-type="fig"}A,B shows a coronal section through the auditory forebrain stained for *Adora1* (red) in a single‐probe ISH assay, counterstained with hematoxylin (light blue). *Adora1* signal was most conspicuous in middle and deep layers of cerebral cortex, cell‐dense domains of the hippocampus, MG, and superior colliculus.

![*Adora1* mRNA expression in a coronal section of the mouse brain at the rostral‐caudal level of A1 and MG. **(A)** *Adora1* signal (red) is prominent in the middle and deep layers of cerebral cortex, cellular regions of the hippocampus, MG, superior colliculus (SC), and pontine gray (PG). Hematoxylin counterstain. **(B)** Schematic reference. Scale bar, 1 mm. **(C)** *Adora1* expression across layers of auditory cortex (A1, primary auditory cortex; AuD, dorsal area; AuV, ventral area; TeA, temporal area). **(D)** *Adora1*, 50% thresholded grayscale image from panel C. Gray masked rectangles indicate the portion of each area measured in calculation of grayscale intensity. **(E)** Plots of average grayscale intensity for A1 (black), AuD (blue), AuV (red). Gray rectangles denote boundaries of L4 and L6, where the main signal peaks were centered. Scale, 250 μm.](AR-301-1882-g002){#ar23907-fig-0002}

Laminar intensity profiles in A1 and adjacent fields (AuD, AuV) (Fig. [2](#ar23907-fig-0002){ref-type="fig"}C--E) highlight the prominent peaks in L6 and secondary peaks centered on L4. Note that L6 peak magnitude was comparable for all three fields, while the L4 peak was higher in A1. Intensity profiles were not measured in MG, where *Adora1* expression was relatively homogeneous across divisions.

In Figures [3](#ar23907-fig-0003){ref-type="fig"} and [4](#ar23907-fig-0004){ref-type="fig"}, duplex ISH labeling of *Adora1* (red) and *Gapdh* (green) (positive control) is illustrated at higher magnification to show labeling at the cellular level. *Adora1* ^*+*^ puncta were concentrated within the somata of neurons and glia in A1 and MG (Figs. [3](#ar23907-fig-0003){ref-type="fig"} and [4](#ar23907-fig-0004){ref-type="fig"}). As shown in the high‐magnification images (panels B--E), puncta numbers varied between cells. Some had low numbers (\<5), while high‐density expression in many other cells merged and could not be individually resolved. Cells with high levels of *Gapdh* (mostly neurons) had higher concentrations of *Adora1* than cells with low *Gapdh* levels (mostly glia).

![Duplex chromogenic ISH in A1. *Adora1* (red) + *Gapdh* (aqua). Hematoxylin counterstain (pale blue). **(A)** *Adora1*/*Gapdh* expression across layers of A1. Insets correspond to locations of images in panels B--E. Scale bar, 250 μm. **(B--E)** 100× DIC images of inset locations in panel A. *Adora1* ^*+*^ puncta (red dots) are concentrated within the somatic cytoplasm, mainly in *Gapdh* ^*+*^ cells. Some cells, often glia (asterisk, panel D) contained no puncta. *Adora1* ^*+*^ puncta were also located along fine peripheral processes (arrowheads). Scale bar, 20 μm.](AR-301-1882-g003){#ar23907-fig-0003}

![Duplex chromogenic ISH in MG. *Adora1* (red) + *Gapdh* (aqua). Hematoxylin counterstain (pale blue). (**A**) *Adora1*/*Gapdh* expression across MG subdivisions (v, ventral; d, dorsal; m, medial/magnocellular) and suprageniculate nucleus (Sg). Insets correspond to panels B--E. Scale bar, 250 μm. (**B--E**) 100× DIC images of inset locations in panel A. *Adora1* ^*+*^ puncta (red dots) are concentrated within the somatic cytoplasm, mainly in *Gapdh* ^*+*^ cells. Some cells, often glia (asterisk, panel D) contained few or no puncta. *Adora1* ^*+*^ puncta were also located along fine peripheral processes (arrowheads). Scale bar, 20 μm.](AR-301-1882-g004){#ar23907-fig-0004}

*Adora1* ^*+*^ puncta were also sparsely distributed in the neuropil, outside of somatic boundaries in A1 and MG (Figs. [3](#ar23907-fig-0003){ref-type="fig"} and [4](#ar23907-fig-0004){ref-type="fig"}, arrowheads). DIC microscopy in panels B--E localized these along thin peripheral processes in the dense neuropil matrix, but the cells of origin could not usually be determined. The numbers of puncta not visibly localized to a cellular compartment (i.e., noise) appeared negligible. Assay specificity for *Adora1* was very high, as evidenced by the near total absence of puncta in cell‐poor zones (Figs. [3](#ar23907-fig-0003){ref-type="fig"}B and [4](#ar23907-fig-0004){ref-type="fig"}B,C). Transcript expression in peripheral processes was also observed for *Aqp4* and *MBP*, described below. See Discussion for more on this subject.

3.2. Co‐Expression of *Adora1* with Neuronal and Glial Markers {#ar23907-sec-0011}
--------------------------------------------------------------

Multiplex fluorescence ISH (FISH) was used to demonstrate co‐expression of markers within cells, and as a positive control to test probe specificity. Figure [5](#ar23907-fig-0005){ref-type="fig"} shows the co‐expression for neuronal and glial markers in auditory cortex (L3). In Figure [5](#ar23907-fig-0005){ref-type="fig"}A, *Adora1* (red) was combined with markers for *VGluT1* (white), *VGluT2* (yellow), and *VGAT* (green). In these neurons, typical of A1 and MG, *Adora1* was co‐expressed with *VGluT1* and *VGluT2*, but not *VGAT*. In Figure [5](#ar23907-fig-0005){ref-type="fig"}B, *Adora1* (red) was combined with markers for *MBP* (white), *Aqp4* (yellow) and *Itgam* (green). The results indicate very low (nominal) expression of *Adora1* within glia, consistent with findings in colorimetric ISH assays (see below). In all panels, the absence of co‐localized signals within puncta ("dots") demonstrates that the markers of each gene were specific to their targets.

![Fluorescence FISH in layer 3 of A1, combining *Adora1* with neuronal or glial markers. (**A**) *Adora1* (red) with neuronal markers: *VGluT1* (white), *VGluT2* (yellow), and *VGAT* (green). (**B**) *Adora1* (red) with glial markers: *MBP*/oligodendrocytes (white)*, Aqp4*/astrocytes (yellow), and *Itgam*/microglia (green). Reactive puncta (dots) of different markers do not colocalize, but may be co‐expressed within the same cell (e.g., *Adora1* + *VGluT1*). Scale bar, 20 μm.](AR-301-1882-g005){#ar23907-fig-0005}

3.3. *Adora1* Expression by Neurons and Glia {#ar23907-sec-0012}
--------------------------------------------

In the remaining assays described below, neuronal and glial markers were paired with *Adora1* in duplex chromogenic assays. Data summaries for each combination are illustrated in Figures [6](#ar23907-fig-0006){ref-type="fig"}, [7](#ar23907-fig-0007){ref-type="fig"}, [8](#ar23907-fig-0008){ref-type="fig"}, [9](#ar23907-fig-0009){ref-type="fig"}, [10](#ar23907-fig-0010){ref-type="fig"}, [11](#ar23907-fig-0011){ref-type="fig"} (neurons) and Figures [12](#ar23907-fig-0012){ref-type="fig"}, [13](#ar23907-fig-0013){ref-type="fig"}, [14](#ar23907-fig-0014){ref-type="fig"}, [15](#ar23907-fig-0015){ref-type="fig"}, [16](#ar23907-fig-0016){ref-type="fig"}, [17](#ar23907-fig-0017){ref-type="fig"} (glia). Cell counts for all combinations are compiled in Figure [18](#ar23907-fig-0018){ref-type="fig"}.

![Duplex chromogenic ISH in A1. *Adora1* (red) + *VGluT1* (aqua). Hematoxylin counterstain (light blue). (**A**) Bright‐field image of A1. Insets correspond to panels i--viii. (**B**) *VGluT1* ^*+*^ cells plotted by cortical layer. Filled circles, co‐expression of *Adora1* + *VGluT1*. Open circles, *VGluT1* ^*+*^ only. Scale bar, 250 μm. (**Panels i--viii**) 100× DIC images of inset locations in panel A. Solid arrows, dual‐labeled; gray arrows, nominal *Adora1* puncta. See text for details. Scale bar, 20 μm.](AR-301-1882-g006){#ar23907-fig-0006}

![Duplex chromogenic ISH in MG. *Adora1* (red) + *VGluT1* (aqua). Hematoxylin counterstain (light blue). (**A**) Bright‐field image of MG. Insets correspond to panels i--viii. (**B**) *VGluT1* ^*+*^ cells plotted by MG subdivision. Filled circles, co‐expression of *Adora1* + *VGluT1*. Open circles, *VGluT1* ^*+*^ only. Scale bar, 250 μm. (**Panels i--viii**) 100× DIC images of inset locations in panel A. Solid arrows, dual‐labeled cells; gray arrows, nominal *VGluT1* puncta in *Adora1* ^*+*^ cell; white arrows, no *VGluT1* detected. Gray arrowheads in panels i--v mark examples of small and out‐of‐focus *VGluT1* ^*+*^ puncta. See text for details. Scale bar, 20 μm.](AR-301-1882-g007){#ar23907-fig-0007}

![Duplex chromogenic ISH in A1. *Adora1* (red) + *VGluT2* (aqua). Hematoxylin counterstain (light blue). (**A**) Bright‐field image of A1. Insets correspond to panels i--viii. (**B**) *VGluT2* ^*+*^ cells plotted by cortical layer. Filled circles, co‐expression of *Adora1* + *VGluT2*. Scale bar, 250 μm. (**Panels i--viii**) 100× DIC images of inset locations in panel A. Solid arrows, dual‐labeled. Note low *VGluT2* expression levels. See text for details. Scale bar, 20 μm.](AR-301-1882-g008){#ar23907-fig-0008}

![Duplex chromogenic ISH in MG. *Adora1* (red) + *VGluT2* (aqua). Hematoxylin counterstain (light blue). (**A**) Bright‐field image of MG. Insets correspond to panels i--viii. (**B**) *VGluT2* ^*+*^ cells plotted by MG subdivision. Filled circles, co‐expression of *Adora1* + *VGluT2*. Open circles, *VGluT2* ^*+*^ only. Scale bar, 250 μm. (**Panels i--viii**) 100× DIC images of inset locations in panel A. Solid arrows, dual‐labeled; gray arrows, nominal *Adora1* puncta. See text for details. Scale bar, 20 μm.](AR-301-1882-g009){#ar23907-fig-0009}

![Duplex chromogenic ISH in A1. *Adora1* (red) + *VGAT* (aqua). Hematoxylin counterstain (light blue). (**A**) Bright‐field image of A1. Insets correspond to panels --i--viii. (**B**) *VGAT* ^*+*^ cells plotted by cortical layer. Filled circles, co‐expression of *Adora1* + *VGAT*. Open circles, *VGAT* only. Scale bar, 250 μm. (**Panels i--viii**) 100× DIC images of inset locations in panel A. Solid arrows, dual‐labeled; gray arrows, nominal *Adora1* puncta. See text for details. Scale bar, 20 μm.](AR-301-1882-g010){#ar23907-fig-0010}

![Duplex chromogenic ISH in MG. *Adora1* (red) + *VGAT* (aqua). Hematoxylin counterstain (light blue). (**A**) Bright‐field image of MG. Insets correspond to panels --i--viii. (**B**) *VGAT* ^*+*^ cells plotted by MG subdivision. Filled circles, co‐expression of *Adora1* + *VGAT*. Open circles, *VGAT* ^*+*^ only. Scale bar, 250 μm. (**Panels i--viii**) 100× DIC images of inset locations in panel A. Solid arrows, dual‐labeled; gray arrows, nominal *Adora1* puncta. See text for details. Scale bar, 20 μm.](AR-301-1882-g011){#ar23907-fig-0011}

![Duplex chromogenic ISH in A1. *Adora1* (red) + *MBP* (aqua). Hematoxylin counterstain (light blue). (**A**) Bright‐field image of A1. Insets correspond to panels --i--viii. (**B**) *MBP* ^*+*^ cells plotted by cortical layer. Filled circles, co‐expression of *Adora1* + *MBP*. Open circles, *MBP* only. White matter, wm. Scale bar, 250 μm. (**Panels i--viii**) 100× DIC images of inset locations in panel A. Solid arrows, dual‐labeled; gray arrows, nominal *Adora1* puncta. Arrowheads, extrasomatic *MBP* ^*+*^ puncta (black) and *Adora1* ^*+*^ puncta (gray). See text for details. Scale bar, 20 μm.](AR-301-1882-g012){#ar23907-fig-0012}

![Duplex chromogenic ISH in MG. *Adora1* (red) + *MBP* (aqua). Hematoxylin counterstain (light blue). (**A**) Bright‐field image of MG. Insets correspond to panels --i--viii. (**B**) *MBP* ^*+*^ cells plotted by MG subdivision. Filled circles, co‐expression of *Adora1* + *MBP*. Open circles, *MBP* ^*+*^ only. Scale bar, 250 μm. (**Panels i--viii**) 100× DIC images of inset locations in panel A. Solid arrows, dual‐labeled; gray arrows, nominal *Adora1* puncta. See text for details. Scale bar, 20 μm.](AR-301-1882-g013){#ar23907-fig-0013}

![Duplex chromogenic ISH in A1. *Adora1* (red) + *Aqp4* (aqua). Hematoxylin counterstain (light blue). (**A**) Bright‐field image of A1. Insets correspond to panels --i--viii. (**B**) *Aqp4* ^*+*^ cells plotted by cortical layer. Filled circles, co‐expression of *Adora1* + *Aqp4*. Open circles, *Aqp4* only. White matter, wm. Scale bar, 250 μm. (**Panels i--viii**) 100× DIC images of inset locations in panel A. Solid arrows, dual‐labeled; gray arrows, nominal *Adora1* puncta. Arrowheads, perivascular *Aqp4* ^*+*^ puncta (gray). See text for details. Scale bar, 20 μm.](AR-301-1882-g014){#ar23907-fig-0014}

![Duplex chromogenic ISH in MG. *Adora1* (red) + *Aqp4* (aqua). Hematoxylin counterstain (light blue). (**A**) Bright‐field image of MG. Insets correspond to panels --i--viii. (**B**) *Aqp4* ^*+*^ cells plotted by MG subdivision. Filled circles, co‐expression of *Adora1* + *Aqp4*. Open circles, *Aqp4* ^*+*^ only. Scale bar, 250 μm. (**Panels i--viii**) 100× DIC images of inset locations in panel A. Solid arrows, dual‐labeled; gray arrows, nominal *Adora1* puncta. Arrowhead (panel v), single *Adora1* puncta within an *Aqp4* ^*+*^ cell. See text for details. Scale bar, 20 μm.](AR-301-1882-g015){#ar23907-fig-0015}

![Duplex chromogenic ISH in A1. *Adora1* (red) + *Itgam* (aqua). Hematoxylin counterstain (light blue). (**A**) Bright‐field image of A1. Insets correspond to panels --i--viii. (**B**) *Itgam* ^*+*^ cells plotted by cortical layer. Filled circles, co‐expression of *Adora1* + *Itgam*. Open circles, *Itgam* only. White matter, wm. Scale bar, 250 μm. (**Panels i--viii**) 100× DIC images of inset locations in panel A. Solid arrows, dual‐labeled; gray arrows, nominal *Adora1* puncta. Arrowhead (panels v, viii), single *Adora1* ^*+*^ puncta within an *Adora1* ^*+*^ cell. See text for details. Scale bar, 20 μm.](AR-301-1882-g016){#ar23907-fig-0016}

![Duplex chromogenic ISH in MG. *Adora1* (red) + *Itgam* (aqua). Hematoxylin counterstain (light blue). (**A**) Bright‐field image of MG. Insets correspond to panels --i--viii. (**B**) *Itgam* ^*+*^ cells plotted by MG subdivision. Filled circles, co‐expression of *Adora1* + *Itgam*. Open circles, *Itgam* ^*+*^ only. Scale bar, 250 μm. (**Panels i--viii**) 100× DIC images of inset locations in panel A. Solid arrows, dual‐labeled; gray arrows, nominal *Adora1* puncta. See text for details. Scale bar, 20 μm.](AR-301-1882-g017){#ar23907-fig-0017}

![Cell counts in A1 and MG for each marker combination. Histograms reflect the mean number of single‐ (blue bars) and dual‐labeled cells (red bars) for each cell type marker. (**A--C**) Neuronal subtypes + *Adora1* in A1 by cortical layer. (**D--E**) Glial subtypes + *Adora1* in A1. (**G--I**) Neuronal subtypes + *Adora1* in MG by division. (**J--L**) Glial subtypes + *Adora1* in MG. Error bars, standard deviation. Note variations in *y*‐axis scale between panels.](AR-301-1882-g018){#ar23907-fig-0018}

Note in figures illustrating duplex labeling, DIC microscopy sometimes caused a slight z‐plane distortion in the green color spectrum, affecting the appearance (size or color) of fast‐green‐labeled puncta. Depending on precise z‐location, labeled puncta could range in color from yellow‐green to blue, and could be quite small. Arrowheads were used to mark illustrative examples of small or out‐of‐focus puncta in some panels, where copy number was low for a given marker.

3.4. *Adora1* Expression by *VGluT1* ^*+*^ Neurons in A1 and MG {#ar23907-sec-0013}
---------------------------------------------------------------

As previously established (Ito and Oliver, [2010](#ar23907-bib-0109){ref-type="ref"}; Hackett et al., [2011b](#ar23907-bib-0097){ref-type="ref"}; Hackett et al., [2016](#ar23907-bib-0099){ref-type="ref"}), *VGluT1* (*Slc17a7*) was expressed by likely all glutamatergic neurons in A1, and a majority of neurons in MGv and MGd (Figs. [6](#ar23907-fig-0006){ref-type="fig"} and [7](#ar23907-fig-0007){ref-type="fig"}). In A1 *Adora1* was coexpressed by the majority of *VGluT1* ^*+*^ neurons in L3--6 (Figs. [6](#ar23907-fig-0006){ref-type="fig"}ii--viii and [18](#ar23907-fig-0018){ref-type="fig"}). Most neurons in L2 had nominal *Adora1* expression, as did a minor subpopulation of *VGluT1* ^*+*^ cells in other layers (Figs. [6](#ar23907-fig-0006){ref-type="fig"}i,vi and [18](#ar23907-fig-0018){ref-type="fig"}). *Adora1* transcripts were most heavily concentrated in *VGluT1* ^*+*^ neurons of L3b/4 and L6 (Fig. [6](#ar23907-fig-0006){ref-type="fig"}iii,iv,vii,viii). Strongly‐labeled cells were present in other layers, as well (Fig. [6](#ar23907-fig-0006){ref-type="fig"}iii), indicating cell‐specific variations in *Adora1* expression, independent of cortical layer.

In MG, *VGluT1* expression was largely restricted to MGv and MGd, as relatively few neurons were *VGluT1* ^*+*^ in MGm (Fig. [7](#ar23907-fig-0007){ref-type="fig"}). *VGluT1* transcript abundance was generally lower in MG neurons, compared to *VGluT2* ^*+*^ neurons in MG (below) or *VGluT1* ^*+*^ neurons in A1 (see examples in Fig. [7](#ar23907-fig-0007){ref-type="fig"}i,ii,v--vii). These distributions are consistent with previous findings (Barroso‐Chinea et al., [2007](#ar23907-bib-0018){ref-type="ref"}; Ito et al., [2011](#ar23907-bib-0110){ref-type="ref"}; Storace et al., [2012](#ar23907-bib-0185){ref-type="ref"}). *Adora1* was expressed in nearly all *VGluT1* ^*+*^ cells in MGv and MGd, while in MGm, the majority of cells expressed *Adora1*, but not *VGluT1* (Figs. [7](#ar23907-fig-0007){ref-type="fig"}iii,iv and [18](#ar23907-fig-0018){ref-type="fig"}).

3.5. *Adora1* Expression by *VGluT2* ^*+*^ Neurons in A1 and MG {#ar23907-sec-0014}
---------------------------------------------------------------

In A1, *VGluT2* (*Slc17a6*) was expressed by a minor subpopulation of neurons that co‐express *VGluT1*, mainly in L3/4, as previously reported (Ito and Oliver, [2010](#ar23907-bib-0109){ref-type="ref"}, Hackett et al., [2011b](#ar23907-bib-0097){ref-type="ref"}, Hackett et al., [2016](#ar23907-bib-0099){ref-type="ref"}). *VGluT2* transcript abundance was relatively low in most cells, compared with *VGluT1* (Fig. [8](#ar23907-fig-0008){ref-type="fig"}i--viii). All of the *VGluT2* ^*+*^ neurons identified in A1 coexpressed *Adora1*, regardless of layer (Figs. [8](#ar23907-fig-0008){ref-type="fig"} and [18](#ar23907-fig-0018){ref-type="fig"}).

In MG, *VGluT2* expression was strong in nearly all neurons in all divisions (Figs. [9](#ar23907-fig-0009){ref-type="fig"} and [18](#ar23907-fig-0018){ref-type="fig"}). The vast majority co‐expressed *Adora1. VGluT2* ^*+*^ cells with nominal *Adora1* expression were rare in MGv and MGd, while slightly more were found in MGm/Sg (Figs. [9](#ar23907-fig-0009){ref-type="fig"}iii and [18](#ar23907-fig-0018){ref-type="fig"}).

3.6. *Adora1* Expression by *VGAT* ^*+*^ Neurons in A1 and MG {#ar23907-sec-0015}
-------------------------------------------------------------

In A1, *VGAT* (*Slc32a1*) was expressed by GABAergic neurons in all layers, with occasional labeling of cells in the white matter (Figs. [10](#ar23907-fig-0010){ref-type="fig"} and [18](#ar23907-fig-0018){ref-type="fig"}). *Adora1* expression by the majority of *VGAT* ^*+*^ neurons was absent or nominal (Fig. [10](#ar23907-fig-0010){ref-type="fig"}i,ii,v,vi--viii), and low‐abundance co‐expression was observed in a minority of GABAergic neurons scattered across L3--L6 (Fig. [10](#ar23907-fig-0010){ref-type="fig"}ii,iv). While the somata of many *VGAT* ^*+*^ cells were isolated from other cell types by neuropil, others were closely opposed to one or more unlabeled cells (likely glia) (Fig. [10](#ar23907-fig-0010){ref-type="fig"}i--iv,vii). At the border between these cells, the clustering of *Adora1* transcripts was common. For plotting, inspection at 100×, DIC was usually required to determine whether the transcripts were located within the *VGAT* ^*+*^ cell or the apposed cell. Most often it was the latter.

In the MG of rodents, GABAergic cells (and therefore *VGAT* ^*+*^ neurons) are uncommon (Winer and Larue, [1996](#ar23907-bib-0213){ref-type="ref"}; Ito et al., [2011](#ar23907-bib-0110){ref-type="ref"}; Yuge et al., [2011](#ar23907-bib-0216){ref-type="ref"}; Hackett et al., [2016](#ar23907-bib-0099){ref-type="ref"}). Consistent with this prior research, the MG contained very few *VGAT* ^*+*^ cells (Figs. [11](#ar23907-fig-0011){ref-type="fig"} and [18](#ar23907-fig-0018){ref-type="fig"}) (note the reduced *y*‐axis scale in Fig. [18](#ar23907-fig-0018){ref-type="fig"}). There was a slight tendency for *VGAT* ^*+*^ cells to more often be found in MGm/Sg. Overall, *Adora1* was expressed at low levels by roughly half of the sparse population of *VGAT* ^*+*^ cells identified anywhere within the MG, with comparable low expression in adjacent nuclei, where *VGAT* ^*+*^ cells were abundant.

3.7. *Adora1* Expression by *MBP* ^*+*^ Cells in A1 and MG {#ar23907-sec-0016}
----------------------------------------------------------

In A1, *MBP* was expressed in the somata of myelinating oligodendrocytes in L2--L6, and in very high numbers in the underlying white matter (Figs. [12](#ar23907-fig-0012){ref-type="fig"} and [18](#ar23907-fig-0018){ref-type="fig"}). *Adora1* was coexpressed by roughly half of the *MBP* ^*+*^ cells in L2--L5 and 66% in L6. In the white matter, only 34% of *MBP* ^*+*^ cells coexpressed *Adora1* (Figs. [12](#ar23907-fig-0012){ref-type="fig"}viii and [18](#ar23907-fig-0018){ref-type="fig"}). Overall, *Adora1* transcript abundance in the cytoplasm of *MBP* ^*+*^ somata was modest, as evident in Figure [12](#ar23907-fig-0012){ref-type="fig"}i--viii (black arrows). *Adora1* ^*+*^ puncta were typically localized near the cell membrane and at the base of peripheral processes extending away from the soma (Fig. [12](#ar23907-fig-0012){ref-type="fig"}iv,vi, gray arrowheads).

In addition to dense concentrations in the somatic cytoplasm, *MBP* ^*+*^ puncta were also located in peripheral processes, distant from cell somata, visible in all panels in Figure [12](#ar23907-fig-0012){ref-type="fig"}. The DIC images (Fig. [12](#ar23907-fig-0012){ref-type="fig"}i--viii, arrowheads) reveal that puncta were typically located in thin processes, often distributed along the trajectory of a single process (Fig. [12](#ar23907-fig-0012){ref-type="fig"}iii,v, black arrowheads). Such processes were found in L1--L6, and especially dense in white matter tracts (Fig. [12](#ar23907-fig-0012){ref-type="fig"}vii,viii, arrowheads). As discussed above, extrasomatic *Adora1* ^*+*^ transcripts could be located along peripheral processes. Typically, extrasomatic *MBP* ^*+*^ and *Adora1* ^*+*^ puncta were not contiguous within processes, but closely apposed puncta were sometimes observed (Fig. [12](#ar23907-fig-0012){ref-type="fig"}ii), suggesting that local translation of both proteins may sometimes occur in contiguous subcellular compartments.

In MG, *MBP* ^*+*^ cells were evenly distributed across divisions (Fig. [13](#ar23907-fig-0013){ref-type="fig"}A). Transcript abundance in the somatic cytoplasm was typically high (Fig. [13](#ar23907-fig-0013){ref-type="fig"}i--viii). As in cortex, *MBP* ^*+*^ puncta were also abundant within extrasomatic processes, often forming continuous trajectories that could be followed for 300 μm, or more, visible as long striations in Figure [13](#ar23907-fig-0013){ref-type="fig"}A,v,vii. These were especially conspicuous in MGv. *Adora1* expression was nominal in the majority of *MBP* ^*+*^ cells in all divisions (Figs. [13](#ar23907-fig-0013){ref-type="fig"}B and [18](#ar23907-fig-0018){ref-type="fig"}). These tended to be located at or near the somatic periphery, often at the base of peripheral processes (Fig. [13](#ar23907-fig-0013){ref-type="fig"}I,iii,iv,vi--viii). In the neuropil, *Adora1* ^*+*^ puncta were occasionally located among *MBP* ^*+*^ puncta within the same peripheral processes.

3.8. *Adora1* Expression by *Aqp4* ^*+*^ Cells in A1 and MG {#ar23907-sec-0017}
-----------------------------------------------------------

In A1, *Aqp4* was expressed by astrocytes within all cortical layers, white matter, pial membranes, and adjacent to blood vessels (Figs. [14](#ar23907-fig-0014){ref-type="fig"} and [18](#ar23907-fig-0018){ref-type="fig"}). *Adora1* was co‐expressed in subpopulations of *Aqp4* ^*+*^ cells in L2--L6 and white matter. The highest concentration of co‐labeled cells was in L6 (Fig. [14](#ar23907-fig-0014){ref-type="fig"}B). As for the other glial cells, *Adora1* transcript abundance was low in astrocytes, compared to neurons (Fig. [14](#ar23907-fig-0014){ref-type="fig"}i--viii). The perivascular (Fig. [14](#ar23907-fig-0014){ref-type="fig"}ii) and pial astrocytes (Fig. [14](#ar23907-fig-0014){ref-type="fig"}i) typically had little to no detectable expression of *Adora1. Aqp4* ^*+*^ puncta were contained within the somatic cytoplasm of most cells, but some were located along fine processes in the extracellular neuropil in all cortical layers.

In MG, *Aqp4* ^*+*^ cells were distributed evenly across divisions (Figs. [15](#ar23907-fig-0015){ref-type="fig"} and [18](#ar23907-fig-0018){ref-type="fig"}). *Adora1* was expressed by most of the astrocytes detected by *Aqp4*. As in A1, *Adora1* transcript abundance was typically low in *Aqp4* ^*+*^ cells within the main body of the MG, and nominal in most perivascular and pial astrocytes (Fig. [15](#ar23907-fig-0015){ref-type="fig"}i--viii). This distinction signals a potential difference in adenosine signaling between astrocytes in these domains in both A1 and MG. *Aqp4* ^*+*^ puncta were also common in fine peripheral processes in the neuropil, and outside of somata along pial and vascular membranes.

3.9. *Adora1* Expression by *Itgam* ^*+*^ Cells in A1 and MG {#ar23907-sec-0018}
------------------------------------------------------------

In A1, *Itgam* ^*+*^ cells were relatively evenly distributed across cortical layers, with higher numbers in white matter (Figs. [16](#ar23907-fig-0016){ref-type="fig"} and [18](#ar23907-fig-0018){ref-type="fig"}). Microglia were often spatially isolated from other cells (Fig. [16](#ar23907-fig-0016){ref-type="fig"}v), but many were found closely opposed to neurons or other cells (Fig. [16](#ar23907-fig-0016){ref-type="fig"}i--iv), consistent with recent studies (Baalman et al., [2015](#ar23907-bib-0010){ref-type="ref"}). The majority of *Itgam* ^*+*^ cells did not co‐express *Adora1*, but often contained 1 or 2 *Adora1* ^*+*^ puncta (gray arrowheads in Fig. [16](#ar23907-fig-0016){ref-type="fig"}i--viii). *Itgam* ^*+*^ puncta were largely confined to somatic cytoplasm, and rarely found in the neuropil along processes.

In MG, *Itgam* ^*+*^ cells were sparsely distributed across divisions, compared to astrocytes and oligodendrocytes (Figs. [17](#ar23907-fig-0017){ref-type="fig"} and [18](#ar23907-fig-0018){ref-type="fig"}). As in cortex, the majority did not co‐express *Adora1*, and *Adora1* transcript abundance in cells identified as co‐labeled was generally very low (near the cutoff of 3 *Adora1* ^*+*^ puncta).

3.10. A~1~R Immunohistochemistry (IHC, FIHC) {#ar23907-sec-0019}
--------------------------------------------

Chromogenic (IHC) and fluorescence (FIHC) assays revealed strong punctate A~1~R immunoreactivity in A1 and MG. Reactivity was concentrated in the neuropil, characterized by dense perisomatic labeling (Fig. [19](#ar23907-fig-0019){ref-type="fig"}A,B) around most cells (Fig. [19](#ar23907-fig-0019){ref-type="fig"}A,B). Sparse labeling was also observed in the somatic cytoplasm, mainly in neurons (DAPI^+^/NeuN^+^), but not presumptive glia (DAPI^+^/NeuN^−^) (Fig. [19](#ar23907-fig-0019){ref-type="fig"}D--F). In A1, immunoreactivity was strong across L2--L6, but the density of reactive puncta was relatively high in L4 (Fig. [19](#ar23907-fig-0019){ref-type="fig"}A), compared to other layers (e.g., L6) (Fig. [19](#ar23907-fig-0019){ref-type="fig"}B) (qualitative impression). In addition to dense perisomatic and neuropil labeling, immunoreactive puncta sometimes formed orderly distributions (strings) along peripheral processes. Examples are shown in Figure [19](#ar23907-fig-0019){ref-type="fig"}D,E. These striations were evident in the densely reactive neuropil of L3/L4 (Fig. [19](#ar23907-fig-0019){ref-type="fig"}D), and also in L5/L6, where puncta were sometimes localized along apical dendrites (Fig. [19](#ar23907-fig-0019){ref-type="fig"}E, arrowheads). These patterns are similar to an earlier study in other forebrain areas using a custom antibody (Ochiishi et al., [1999](#ar23907-bib-0153){ref-type="ref"}), in which A~1~Rs were localized to pre‐ and postsynaptic compartments of neurons.

![*Adora1* (A~1~R) IHC. (A) A~1~R (green) and NeuN (red) FIHC. Low‐magnification view of auditory forebrain and surrounding structures. Insets correspond to panels D--G. (**B, C**) Bright‐field images of single chromogen A~1~R IHC in A1 layer 4 (**B**) and layer 6 (**C**). (**D, E**) FIHC showing A~1~R (green), NeuN (red), and DAPI (blue). (**D**) A1 layer 4. (**E**) A1 layer 6. Arrowheads show strings of A~1~R‐immunoreactive puncta. (**F**) MGv. (**G**) CA3 region of hippocampus. Scale bars: (**A**) 500 μm; (**B--F**) 20 μm; (**G**) 50 μm.](AR-301-1882-g019){#ar23907-fig-0019}

4. DISCUSSION {#ar23907-sec-0020}
=============

The main purpose of this study was to map the distributions of neuronal and glial cell types that express *Adora1* transcripts in the auditory forebrain of adult mice. A general finding was that *Adora1* is strongly expressed by the vast majority of glutamatergic neurons in A1 and MG, and expressed at lower levels by subpopulations of GABAergic neurons, astrocytes, myelinating oligodendrocytes, and microglia. These patterns reveal regional and cell‐type specificity in *Adora1* expression, and suggest functional differences in adenosine signaling mediated by the A~1~R receptor.

The discussion begins with a brief overview of adenosine signaling, which depends heavily on studies in hippocampus, striatum, and other brain regions. This is followed by discussion of A~1~R‐mediated contributions to synaptic plasticity in the auditory forebrain. The balance of the discussion is devoted to integrating the findings of this study with existing models of auditory forebrain circuitry, along with directions for future study.

4.1. Sources of Adenosine and A~1~R‐Mediated Signaling in the Forebrain {#ar23907-sec-0021}
-----------------------------------------------------------------------

Adenosine plays important roles in the modulation of neuronal activity and neuro--glial interactions in the brain (Burnstock, [2007](#ar23907-bib-0036){ref-type="ref"}; Boison, [2008a](#ar23907-bib-0029){ref-type="ref"}; Abbracchio et al., [2009](#ar23907-bib-0001){ref-type="ref"}; Housley et al., [2009](#ar23907-bib-0104){ref-type="ref"}; Koles et al., [2016](#ar23907-bib-0128){ref-type="ref"}). Multiple sources of extracellular adenosine have been identified, and their respective contributions in this complex system continue to be studied. The two main categories are direct release by neurons and an indirect process involving catabolism of ATP released by neurons and glia (Fig. [20](#ar23907-fig-0020){ref-type="fig"}C) (Fredholm et al., [2005](#ar23907-bib-0082){ref-type="ref"}; Wall and Dale, [2013](#ar23907-bib-0203){ref-type="ref"}; Sebastiao and Ribeiro, [2015](#ar23907-bib-0179){ref-type="ref"}; Cunha, [2016](#ar23907-bib-0059){ref-type="ref"}). Direct neuronal release of adenosine, which may be pre‐ or postsynaptic, appears to be the main source and is achieved by vesicle‐mediated excocytosis or translocation through bidirectional equilibrative nucleoside transporters (ENTs) (Fredholm and Hedqvist, [1980](#ar23907-bib-0081){ref-type="ref"}; Mitchell et al., [1993](#ar23907-bib-0146){ref-type="ref"}; Manzoni et al., [1994](#ar23907-bib-0138){ref-type="ref"}; Brundege and Dunwiddie, [1996](#ar23907-bib-0034){ref-type="ref"}; Wall and Dale, [2008](#ar23907-bib-0202){ref-type="ref"}; Klyuch et al., [2012](#ar23907-bib-0127){ref-type="ref"}; Lovatt et al., [2012](#ar23907-bib-0135){ref-type="ref"}; Melani et al., [2012](#ar23907-bib-0141){ref-type="ref"}). ATP released by glia and neurons may be converted to AMP and adenosine by ectonucleotidases (ENase), including ecto‐5′‐nucleotidase (Nt5e) (Lloyd et al., [1993](#ar23907-bib-0134){ref-type="ref"}; Zhang et al., [2003](#ar23907-bib-0220){ref-type="ref"}; Pascual et al., [2005](#ar23907-bib-0159){ref-type="ref"}; Lovatt et al., [2012](#ar23907-bib-0135){ref-type="ref"}; Zimmermann et al., [2012](#ar23907-bib-0225){ref-type="ref"}; Lalo et al., [2014](#ar23907-bib-0130){ref-type="ref"}). Basal levels of extracellular adenosine are typically maintained at low concentrations (Cunha, [2001](#ar23907-bib-0058){ref-type="ref"}; Boison, [2006](#ar23907-bib-0028){ref-type="ref"}), sufficient to affect tonic activation of A~1~Rs and inhibitory tone (Fredholm, [2007](#ar23907-bib-0078){ref-type="ref"}, [2012](#ar23907-bib-0079){ref-type="ref"}; Lalo et al., [2014](#ar23907-bib-0130){ref-type="ref"}). ENTs on neurons and glia (especially astrocytes) at the synapse help to maintain basal levels and restore balance after activity‐related increases in extracellular adenosine levels, which primarily result from neuronal release (Fredholm et al., [2005](#ar23907-bib-0082){ref-type="ref"}; Dale, [2008](#ar23907-bib-0061){ref-type="ref"}; Boison et al., [2010](#ar23907-bib-0033){ref-type="ref"}; Lovatt et al., [2012](#ar23907-bib-0135){ref-type="ref"}). ENT activity is regulated by adenosine receptor activation through intracellular protein kinase pathways (e.g., adenosine kinase, ADK) responsible for adenosine metabolism (Boison, [2013](#ar23907-bib-0031){ref-type="ref"}).

![Schematic summaries of *Adora1* mRNA expression in the auditory forebrain (left) and adenosine signaling at a glutamatergic synapse (right). Symbol keys for A--C below each panel. (**A**) *Adora1* expression by glutamatergic (triangles) and GABAergic (circles) neurons in A1 and MG. Filled symbols denote *Adora1* ^*+*^ cells. White fill, *Adora1* ^*−*^. Arrows summarize thalamocortical (TC), corticocortical (CC), corticothalamic (CT), and corticotectal (Ct) projections of VGluT1/A~1~R and VGluT2/A~1~R containing neurons in A1 and MG. Line thickness corresponds to projection strength. Background shading in A1 layers represents relative density of VGluT2/A~1~R TC inputs from MG (Hackett et al., [2016](#ar23907-bib-0099){ref-type="ref"}). (**B**) *Adora1* expression by astrocytes (circles), oligodendrocytes (ovals), and microglia (triangles) in A1 and MG. Filled symbols denote *Adora1* ^*+*^ cells. White fill, *Adora1* ^*−*^. (**C**) Schematic highlighting basic elements of adenosine signaling at a glutamatergic synapse. Adenosine (ADO, red circles) and ATP (blue circles) are released mainly by neurons, astrocytes, and/or microglia by several mechanisms, including exocytosis and translocation through equilibrative nucleoside transporters (ENTs) and connexin/pannexin hemichannels. Intracellular adenosine levels are controlled by a cycle involving adenosine kinase (ADK) and ecto‐5′‐nucleotidase (Nt5E). Extracellular adenosine levels are regulated *via* catabolism of ATP by ectonucleotidases (ENase, Nt5E). Adenosine (A~1~R) and ATP (P~2~ class) receptors occupy pre‐ and postsynaptic neuronal membranes, astrocytes, microglia, and oligodendrocytes. Cholinergic binding of presynaptic M~1~ acetylcholine receptors interferes with A~1~R signaling, permitting sustained glutamate release. Group 1 mGluRs mediate LTP and LTD in TC projections. Model compiled from present and prior studies reviewed in the Discussion. For simplicity, only the most relevant signaling cascades and receptors are included. Some details may vary by brain region and cell type, and are subject to later revision.](AR-301-1882-g020){#ar23907-fig-0020}

Adenosine signaling is mainly achieved through G‐protein‐coupled A~1~Rs, the most highly expressed of the four receptor subtypes. In neurons, A~1~Rs occupy pre‐ and postsynaptic sites, but abundance appears to be highest in presynaptic terminals (Tetzlaff et al., [1987](#ar23907-bib-0188){ref-type="ref"}; Ochiishi et al., [1999](#ar23907-bib-0153){ref-type="ref"}; Rebola et al., [2003](#ar23907-bib-0166){ref-type="ref"}; Rebola et al., [2005](#ar23907-bib-0167){ref-type="ref"}). The primary action of A~1~R‐mediated adenosine signaling at excitatory synapses is presynaptic inhibition of glutamate release, which is increased by interfering with A~1~R activation (Fredholm and Dunwiddie, [1988](#ar23907-bib-0080){ref-type="ref"}; Dunwiddie and Masino, [2001](#ar23907-bib-0069){ref-type="ref"}; Fredholm et al., [2005](#ar23907-bib-0082){ref-type="ref"}). Postsynaptic effects involving A~1~Rs include decreased activation of ionotropic NMDA receptors and ion channel conductances (Proctor and Dunwiddie, [1987](#ar23907-bib-0165){ref-type="ref"}; Klishin et al., [1995a](#ar23907-bib-0125){ref-type="ref"}; Klishin et al., [1995b](#ar23907-bib-0126){ref-type="ref"}; Wetherington and Lambert, [2002](#ar23907-bib-0210){ref-type="ref"}; Chung et al., [2009](#ar23907-bib-0047){ref-type="ref"}; Kim and Johnston, [2015](#ar23907-bib-0121){ref-type="ref"}). Through these mechanisms, activity‐dependent adenosine signaling through A~1~Rs contributes to adaptive changes in neurotransmission associated with various processes, such as neuroprotection and plasticity.

4.2. Adenosine Signaling and Synaptic Plasticity in the Auditory Forebrain {#ar23907-sec-0022}
--------------------------------------------------------------------------

The mechanisms that contribute to synaptic plasticity in the auditory forebrain remain the subject of intensive research, as their elucidation is essential for improved understanding of learning and memory (Weinberger, [2007](#ar23907-bib-0209){ref-type="ref"}), reorganization/augmentation of stimulus representations (Fritz et al., [2007](#ar23907-bib-0084){ref-type="ref"}; Sanes and Bao, [2009](#ar23907-bib-0174){ref-type="ref"}; Schreiner and Polley, [2014](#ar23907-bib-0177){ref-type="ref"}), and critical periods (Bavelier et al., [2010](#ar23907-bib-0019){ref-type="ref"}; Froemke and Jones, [2011](#ar23907-bib-0085){ref-type="ref"}; Takesian and Hensch, [2013](#ar23907-bib-0187){ref-type="ref"}). Critical periods form as synaptic machinery stabilizes during postnatal development, and plasticity at both corticocortical and thalamocortical synapses is dampened, limiting the changes in activity that can be induced by experience (Zhang and Poo, [2001](#ar23907-bib-0218){ref-type="ref"}; Sanes and Woolley, [2011](#ar23907-bib-0175){ref-type="ref"}). Thalamocortical synapses become especially resistant to change with maturation (Crair and Malenka, [1995](#ar23907-bib-0052){ref-type="ref"}; Barkat et al., [2011](#ar23907-bib-0017){ref-type="ref"}; Chun et al., [2013](#ar23907-bib-0046){ref-type="ref"}), whereas prior to critical period closure, even passive exposure to a sound is sufficient to induce changes (Zhang et al., [2001](#ar23907-bib-0219){ref-type="ref"}; de Villers‐Sidani et al., [2007](#ar23907-bib-0064){ref-type="ref"}; Insanally et al., [2009](#ar23907-bib-0108){ref-type="ref"}; Barkat et al., [2011](#ar23907-bib-0017){ref-type="ref"}). Yet, plasticity can still be induced in mature TC and CC synapses by an active process, such as attention to behaviorally relevant sounds (Recanzone et al., [1993](#ar23907-bib-0168){ref-type="ref"}; Blake et al., [2002](#ar23907-bib-0023){ref-type="ref"}; Edeline, [2003](#ar23907-bib-0070){ref-type="ref"}; Keeling et al., [2008](#ar23907-bib-0117){ref-type="ref"}; Sarro et al., [2015](#ar23907-bib-0176){ref-type="ref"}), electrical stimulation of MG (Jafari et al., [2007](#ar23907-bib-0111){ref-type="ref"}; Ma and Suga, [2009](#ar23907-bib-0137){ref-type="ref"}; Zhu et al., [2014](#ar23907-bib-0223){ref-type="ref"}), or other forms of neuromodulation (Edeline, [2003](#ar23907-bib-0070){ref-type="ref"}; Metherate, [2004](#ar23907-bib-0142){ref-type="ref"}; Metherate and Hsieh, [2004](#ar23907-bib-0144){ref-type="ref"}; Weinberger, [2004](#ar23907-bib-0208){ref-type="ref"}; Froemke and Jones, [2011](#ar23907-bib-0085){ref-type="ref"}; Metherate, [2011](#ar23907-bib-0143){ref-type="ref"}; Edeline, [2012](#ar23907-bib-0071){ref-type="ref"}; Blundon and Zakharenko, [2013](#ar23907-bib-0024){ref-type="ref"}; Takesian and Hensch, [2013](#ar23907-bib-0187){ref-type="ref"}). For example, merely pairing the release of acetylcholine with a sound is sufficient to increase neuronal responsiveness to that stimulus (Bao et al., [2003](#ar23907-bib-0015){ref-type="ref"}).

Taken together, these findings imply that plasticity becomes limited during maturation by the establishment of gating mechanisms, which can subsequently be altered under various conditions to permit plasticity. Although many factors are very well known (e.g., acetylcholine, GABA), the roles of other players, such as adenosine, continue to be identified and refined. In hippocampus and other brain regions, adenosine can regulate synaptic transmission and plasticity through A~1~ and A~2a~ receptors, located at pre‐ and postsynaptic sites on neurons and astrocytes (Sebastiao and Ribeiro, [2009](#ar23907-bib-0178){ref-type="ref"}; Sperlagh and Vizi, [2011](#ar23907-bib-0182){ref-type="ref"}; Dias et al., [2013](#ar23907-bib-0066){ref-type="ref"}; Ota et al., [2013](#ar23907-bib-0156){ref-type="ref"}; Chen et al., [2014](#ar23907-bib-0044){ref-type="ref"}; Sebastiao and Ribeiro, [2015](#ar23907-bib-0179){ref-type="ref"}). In somatosensory cortex, for example, adenosine application downregulated glutamate release from TC synapses, while A~1~R inhibition prevented this effect, enabling the modulation of short‐term plasticity (Ferrati et al., [2016](#ar23907-bib-0074){ref-type="ref"}).

In auditory cortex, a series of studies revealed that adenosine signaling through A~1~Rs is a major factor in gating thalamocortical (TC) plasticity after the early critical period. Blundon et al. ([2011](#ar23907-bib-0025){ref-type="ref"}) showed that postsynaptic LTD depends on group 1 metabotropic glutamate receptors (mGluR~1~), but is gated *presynaptically* at mature synapses in A1 by mechanisms that involve adenosine. Briefly, they found that activation of presynaptic M~1~ acetylcholine receptors (M~1~Rs) interfered with adenosine‐A~1~R signaling downstream, permitting sustained glutamate release and LTD induction. Further, inhibition or deletion of A~1~Rs was sufficient to release this gating. Chun et al. ([2013](#ar23907-bib-0046){ref-type="ref"}) showed that postsynaptic LTP in TC synapses in A1 also depends on Group 1 mGluRs (mGluR~1~, mGluR~5~), but not NMDARs, and becomes gated during maturation. In A1 of adult animals, TC LTP could be induced by combining cholinergic release with disinhibition, but not by either mechanism alone. As in the LTD study, cholinergic activation triggered sustained glutamate release by negative regulation of adenosine‐A~1~R signaling, unmasking LTP. In A~1~R^−/−^ knockout mice, LTP could be induced even when M~1~Rs were blocked, indicating that the cholinergic inputs are not required when A~1~Rs have been removed. Most recently, this line of work was extended by this group to receptive field plasticity, *in vivo* (Blundon et al., [2017](#ar23907-bib-0026){ref-type="ref"}). As noted above, passive exposure to a pure tone in an enriched acoustic environment is sufficient to alter receptive fields and expand map representation of that tone in A1 neurons of immature animals, but not adults. In this study, interfering with A~1~Rs in the MG of adult animals by any of several methods (deletion, knockdown, and inhibition) restored map plasticity in A1 and improved tone discrimination after pairing with passive exposure to a pure tone probe. A~1~R agonists inhibited map plasticity. Thus, the maturation of adenosine‐A~1~R signaling in TC synapses acts as a gate, limiting the expression of TC plasticity in adults. Removal of that gating mechanism enables TC synaptic plasticity (Fig. [20](#ar23907-fig-0020){ref-type="fig"}c).

The time course of these effects parallels the maturational trajectory of adenosine receptor expression in the mouse auditory forebrain. In previous work, we generated whole genome transcriptome profiles of A1 and MG, highlighting expression trajectories for over 200 gene families at key stages during postnatal development in mice (P7, P14, P21, adult) (Hackett et al., [2015](#ar23907-bib-0098){ref-type="ref"}; Guo et al., [2016](#ar23907-bib-0094){ref-type="ref"}). For the adenosine receptor family, *Adora1* transcript expression was dominant in A1 and MG, compared to very low expression of *Adora2a* and *Adora2b* (Fig. [1](#ar23907-fig-0001){ref-type="fig"}), consistent with studies in other brain regions (Cahoy et al., [2008](#ar23907-bib-0041){ref-type="ref"}; Zhang et al., [2014](#ar23907-bib-0221){ref-type="ref"}; Zeisel et al., [2015](#ar23907-bib-0217){ref-type="ref"}). We also found that *Adora1* expression increased sharply from P7 to P14 in A1 and MG, and then remained elevated through adulthood. This upregulation is notable, as the P7--P14 interval spans the period before and after hearing onset, and the closing of the early critical period (de Villers‐Sidani et al., [2007](#ar23907-bib-0064){ref-type="ref"}, Insanally et al., [2009](#ar23907-bib-0108){ref-type="ref"}, Barkat et al., [2011](#ar23907-bib-0017){ref-type="ref"}). Rapid upregulation during this period has been noted in other brain regions (Rivkees, [1995](#ar23907-bib-0169){ref-type="ref"}). In addition, we found that expression of several neurotransmitter receptors (e.g., M~1~R) and numerous coding and noncoding genes known to be involved in critical periods plasticity were in flux during this time interval, suggesting that activity‐dependent mechanisms may alter expression among networks of genes (Hackett et al., [2015](#ar23907-bib-0098){ref-type="ref"}; Guo et al., [2016](#ar23907-bib-0094){ref-type="ref"}; Hackett et al., [2016](#ar23907-bib-0099){ref-type="ref"}).

Although not a focus of this study, it may be important context for future purposes that several P~2~ ATP receptors were significantly expressed in the auditory forebrain, and that levels changed from P7 to adult (Fig. [1](#ar23907-fig-0001){ref-type="fig"}). For example, *P2rx2* was expressed at low levels at P7, then dropped to nominal levels by P14; *P2rx4* expression steadily increased from P7 to adult; and *P2ry12* increased sharply from P7 to P14 in A1 and MG. The roles of P~2~ receptors are poorly understood in sensory forebrain regions, but intensive studies elsewhere in the brain reveal important roles in plasticity and development (Zimmermann, [2011](#ar23907-bib-0224){ref-type="ref"}; Sebastiao and Ribeiro, [2015](#ar23907-bib-0179){ref-type="ref"}). Thus, there is likely much more to learn about purinergic and other signaling mechanisms with respect to synaptic plasticity and the establishment of critical periods. These data can serve to guide focused inquiries.

4.3. *Adora1* Expression by Neurons in the MG {#ar23907-sec-0023}
---------------------------------------------

In the MG, *Adora1* expression by neurons was almost entirely restricted to glutamatergic neurons, as GABAergic neurons are rare in the rodent MG. Expression was uniform within and across subdivisions, implying that adenosine utilization is comparable across the cell populations within parallel pathways represented in the MG (Fig. [20](#ar23907-fig-0020){ref-type="fig"}A). These results indicate that A~1~R‐adenosine signaling could impact the presynaptic activity of TC projections MG to all areas of auditory cortex (primary and secondary), as well as descending projections to auditory brainstem (e.g., inferior colliculus). These patterns are consistent with autoradiographic binding studies of A~1~Rs in several species (Fastbom et al., [1987](#ar23907-bib-0073){ref-type="ref"}), and also support recent observations (discussed above) that A~1~Rs located on TC terminals in L3/L4 of A1 modulate presynaptic glutamate release with profound effects on excitatory transmission and synaptic plasticity (Blundon and Zakharenko, [2013](#ar23907-bib-0024){ref-type="ref"}; Chun et al., [2013](#ar23907-bib-0046){ref-type="ref"}; Blundon et al., [2017](#ar23907-bib-0026){ref-type="ref"}).

With this functionality in mind, the expression patterns in MG raise several questions for consideration and future study. First, do presynaptic A~1~Rs on TC projections modulate glutamate release in other thalamorecipient layers of auditory cortex (e.g., L1, L6)? This is a reasonable hypothesis, given that MG neurons co‐express *VGluT2* and *Adora1* transcripts, and immunoreactive terminals are present in all thalamorecipient layers (Fig. [19](#ar23907-fig-0019){ref-type="fig"}) (Hackett et al., [2011b](#ar23907-bib-0097){ref-type="ref"}; Hackett et al., [2016](#ar23907-bib-0099){ref-type="ref"}). Second, does adenosine signaling mediate the same functions in auditory cortical areas other than A1? Strong *Adora1* expression in all MG subdivisions suggests that presynaptic A~1~ receptors are localized on TC inputs to all areas of auditory cortex, not just A1 (Fig. [20](#ar23907-fig-0020){ref-type="fig"}A). Third, do the descending projections of MG neurons to the inferior colliculus and other subcortical targets bear presynaptic A~1~ receptors? If so, are they also involved in the modulation of glutamate release? This seems likely, given that A~1~R‐adenosine signaling has similar effects across brain regions (Cunha, [2016](#ar23907-bib-0059){ref-type="ref"}).

4.4. *Adora1* Expression by Neurons in A1 {#ar23907-sec-0024}
-----------------------------------------

As summarized in Figure [20](#ar23907-fig-0020){ref-type="fig"}A, inputs to A1 include laminar‐specific thalamic and cortical projections, mainly from MG and from other auditory cortical fields. The downstream targets of A1 projection neurons vary by layer of origin, and include both cortical and subcortical targets in both hemispheres. The findings of this study indicate that *Adora1* was expressed by the majority of glutamatergic neurons in L3--L6 of A1, based on co‐expression with *VGluT1* and/or *VGluT2*. In contrast, *Adora1* was expressed with relatively low abundance in a small subpopulation of GABAergic neurons. Expression varied by layer, characterized by the highest levels in L6, intermediate in L3--L5, and nominal in L1--L2. These laminar patterns were maintained in the belt areas surrounding A1, as well as in frontal and other sensory cortical regions (data not shown), suggesting common organizational principles across cortical fields.

A~1~R immunohistochemistry revealed dense punctate expression in the neuropil and perisomatic domains, suggesting utilization of A~1~Rs at pre‐ and postsynaptic sites, as observed in other brain regions (Tetzlaff et al., [1987](#ar23907-bib-0188){ref-type="ref"}; Ochiishi et al., [1999](#ar23907-bib-0153){ref-type="ref"}; Rebola et al., [2003](#ar23907-bib-0166){ref-type="ref"}; Rebola et al., [2005](#ar23907-bib-0167){ref-type="ref"}). Ochiishi et al. ([1999](#ar23907-bib-0153){ref-type="ref"}) found A~1~R expression mainly in layers 2--6 in most areas of cerebral cortex. Light and electron microscopy revealed expression in presynaptic terminals, postsynaptic membranes, and some expression in the somato‐dendritic cytoplasm. They suggested that the latter might reflect active transport of A~1~Rs to synaptic membranes. Thus, the combined ISH and IHC results suggest that *Adora1* transcripts are concentrated in the somatic cytoplasm, while the translated receptor proteins are transported to cell membranes (Fig. [20](#ar23907-fig-0020){ref-type="fig"}). These expression patterns raise several questions about A~1~R‐adenosine signaling in A1.

First, what are the roles of A~1~Rs in the cortico‐cortical and cortico‐fugal projections of A1 neurons? Neurons in L3/L5/L6 project to a wide range of cortical and subcortical targets (Fig. [20](#ar23907-fig-0020){ref-type="fig"}). Briefly, neurons in L6, which had the highest *Adora1* expression levels, project to MG and IC, and receive inputs from the MG and cortical neurons in other locations. Neurons in L5 have widespread subcortical, corticocortical, or callosal projections, depending on the subpopulation. Neurons in L4 receive dense projections from the MG and have largely local projections. L3 neurons also receive thalamic inputs, and have local and longer range corticocortical and callosal projections. Is presynaptic A~1~R‐adenosine signaling also involved in regulating glutamate release in *all* of these projections? It may be significant that while plasticity becomes gated at mature TC synapses, cortico‐cortical synapses remain plastic after critical periods close (Amitai, [2001](#ar23907-bib-0005){ref-type="ref"}; Froemke et al., [2007](#ar23907-bib-0086){ref-type="ref"}; Jiang et al., [2007](#ar23907-bib-0112){ref-type="ref"}; Oswald and Reyes, [2008](#ar23907-bib-0154){ref-type="ref"}, [2011](#ar23907-bib-0155){ref-type="ref"}; Huang et al., [2012](#ar23907-bib-0106){ref-type="ref"}), suggesting different regulatory mechanisms for TC and CC projections. Indeed, whereas interference with A~1~R‐adenosine signaling in MG was sufficient to restore cortical map plasticity, the same manipulations at corticocortical synapses in A1 were not (Blundon et al., [2017](#ar23907-bib-0026){ref-type="ref"}). The reasons remain unknown. Thus, presynaptic A~1~R‐adenosine gating may be specific to TC projections, but have other functions in CC or corticofugal projections.

Second, what is the significance of different *Adora1* expression levels between neurons or across cortical layers? *Adora1* was widely expressed by glutamatergic neurons in L3--L6, but levels varied significantly between layers in A1, the belt areas bordering A1 (AuV, AuD), and in the cortical domains of other sensory modalities (Fig. [2](#ar23907-fig-0002){ref-type="fig"}), suggesting functional homologies among sensory cortical areas. Unfortunately, the precise nature of the relationship between transcript and receptor density in different cellular compartments is not straightforward. In addition to variation in the regulation of transcription or translation, mRNA transcripts and proteins may be localized to different subcellular compartments. For example, studies in hippocampus identified a mismatch between *Adora1* mRNA and A~1~R protein expression, largely explained by the fact that A~1~Rs are concentrated in presynaptic terminals located in brain regions distant from their mRNA‐containing somata (Johansson et al., [1993](#ar23907-bib-0113){ref-type="ref"}; Swanson et al., [1995](#ar23907-bib-0186){ref-type="ref"}). In this study, *Adora1* mRNA expression was highest in neuronal somata of L6, followed by L3/L4, whereas punctate A~1~R immunoreactivity was highest in L3/L4, followed by L6, consistent with findings in several species (Fastbom et al., [1987](#ar23907-bib-0073){ref-type="ref"}). This mismatched laminar pattern partly reflects the high density of immunoreactive TC terminals in L3/L4 from *Adora1* ^*+*^ projection neurons in the MG, and naturally parallels VGluT2 expression patterns in the auditory forebrain (Hackett et al., [2016](#ar23907-bib-0099){ref-type="ref"}). That is, VGluT2 immunoreactive terminals are most highly expressed in L3/4, followed by L6 (similar to A~1~R), and *VGluT2* and *Adora1* mRNA are co‐expressed by perhaps all glutamatergic neurons in MG. Thus, there is a general correspondence in the expression patterns of *VGluT2* and *Adora1* mRNA and their associated proteins in the TC circuit, reflecting the functional link between presynaptic adenosine and glutamate (Fig. [20](#ar23907-fig-0020){ref-type="fig"}).

By extension, such anatomical relationships may be expected to apply to other projections. For example, *VGluT1* ^*+*^ neurons in L6, which have the highest *Adora1* mRNA expression in A1, are the source of a dense network of descending projections to multiple subcortical nuclei in thalamus and brainstem (Bajo et al., [1995](#ar23907-bib-0014){ref-type="ref"}; Winer, [2005](#ar23907-bib-0212){ref-type="ref"}; Bajo and King, [2012](#ar23907-bib-0013){ref-type="ref"}; Crandall et al., [2015](#ar23907-bib-0053){ref-type="ref"}; Guo et al., [2017](#ar23907-bib-0095){ref-type="ref"}) (Fig. [20](#ar23907-fig-0020){ref-type="fig"}). A reasonable prediction is that presynaptic A~1~R‐adenosine signaling is important in the modulatory environment of those projections, as well. Conversely, A~1~R‐adenosine signaling could be considered relatively less important for neurons in superficial cortical layers (e.g., L2), where *Adora1* expression is nominal. These relationships are reflected in the summary diagram of Figure [20](#ar23907-fig-0020){ref-type="fig"}A, where A~1~R expression is contained in *VGluT1* ^*+*^ or *VGluT2* ^*+*^ neurons in corticocortical (CC), thalamocortical (TC), corticothalamic (CT), and corticotectal (Ct) projection systems in the auditory forebrain.

Third, in addition to laminar differences in expression, there was diversity among neurons within the same layers. For example, *Adora1* ^*+*^ puncta numbers were very high in some *VGluT1* ^*+*^ neurons, but not others (Fig. [6](#ar23907-fig-0006){ref-type="fig"}). Because the projections of neurons within the same cortical layer can vary significantly (i.e., cortico‐cortical, cortico‐thalamic, cortico‐tectal), differences in A~1~R utilization may also vary by neuronal subpopulation, perhaps in a manner related to connectivity in the network. Indeed, the anatomical and physiological characteristics of neurons in the same cortical layer are often distinct, and those differences linked to their transcriptional heterogeneity (Chevee et al., [2018](#ar23907-bib-0045){ref-type="ref"}). Further, *Adora1* expression was relatively low in the majority of GABAergic neurons. Roughly 20% of *VGAT* ^+^ neurons in A1 were identified as *Adora1* ^*+*^, but most contained just a few puncta, and higher numbers were restricted to a minor subpopulation. The identity of that subpopulation is not yet known. Functionally, the implications are not clear, as adenosine signaling has not been studied in GABAergic neurons in A1. Elsewhere in the brain (e.g., hippocampus), A~1~R expression is strong in most glutatamatergic neurons, but tends to be significant only in subpopulations of GABAergic interneurons (Rivkees et al., [1995](#ar23907-bib-0170){ref-type="ref"}; Ochiishi et al., [1999](#ar23907-bib-0153){ref-type="ref"}; Zeisel et al., [2015](#ar23907-bib-0217){ref-type="ref"}). Accordingly, GABA release is often not influenced by activation of A~1~Rs (Cunha and Ribeiro, [2000](#ar23907-bib-0060){ref-type="ref"}; Cristovao‐Ferreira et al., [2009](#ar23907-bib-0054){ref-type="ref"}). However, in a specific CA1 interneuron subtype, downregulation of extrasynaptic GABA~A~ receptors by adenosine disinhibits those GABAergic interneurons (Klausberger et al., [2005](#ar23907-bib-0124){ref-type="ref"}; Rombo et al., [2016](#ar23907-bib-0171){ref-type="ref"}). Alternatively, adenosine signaling can regulate synaptic GABA levels *via* astrocytic transport initiated by activation of A~1~--A~2a~ heteromers on astrocytes (Cristovao‐Ferreira et al., [2013](#ar23907-bib-0055){ref-type="ref"}). Thus, the impact of A~1~R‐mediated adenosine signaling on GABAergic inhibition in auditory forebrain may operate through such indirect mechanisms and involve particular neuronal classes.

Last, what are the impacts of postsynaptic A~1~R‐adenosine signaling on neurons in A1? Are the effects different for A~1~Rs located on somata or dendrites? The expression patterns identified here imply that adenosine signaling *via* postsynaptic A~1~ receptors could influence the activity of glutamatergic neurons in L3--L6 of auditory cortex, and perhaps a subpopulation of GABAergic cells, consistent with findings in other brain regions (Abbracchio et al., [2009](#ar23907-bib-0001){ref-type="ref"}; Wei et al., [2011](#ar23907-bib-0207){ref-type="ref"}; Lovatt et al., [2012](#ar23907-bib-0135){ref-type="ref"}; Dias et al., [2013](#ar23907-bib-0066){ref-type="ref"}). Functionally, studies conducted primarily in hippocampus indicate that the postsynaptic effects of A~1~R activation typically include decreased activation of ionotropic NMDA receptors and associated cation channel conductances, while A~1~R blockade has the opposite effect (Proctor and Dunwiddie, [1987](#ar23907-bib-0165){ref-type="ref"}; Klishin et al., [1995a](#ar23907-bib-0125){ref-type="ref"}; Klishin et al., [1995b](#ar23907-bib-0126){ref-type="ref"}; Wetherington and Lambert, [2002](#ar23907-bib-0210){ref-type="ref"}; Chung et al., [2009](#ar23907-bib-0047){ref-type="ref"}; Kim and Johnston, [2015](#ar23907-bib-0121){ref-type="ref"}). Moreover, these effects can vary regionally by neuronal subpopulation and A~1~R expression density (Lee et al., [1983](#ar23907-bib-0132){ref-type="ref"}; Kim and Johnston, [2015](#ar23907-bib-0121){ref-type="ref"}), indicating that properties may vary by specific location or cell type. As mentioned above, induction of LTD, LTP and receptive field plasticity in auditory cortex was distinct for pre‐ and postsynaptic A~1~Rs (Blundon et al., [2011](#ar23907-bib-0025){ref-type="ref"}; Chun et al., [2013](#ar23907-bib-0046){ref-type="ref"}; Blundon et al., [2017](#ar23907-bib-0026){ref-type="ref"}), highlighting potential differences in pre‐ or postsynaptic A~1~R‐adenosine signaling.

4.5. *Adora1* Expression by Glia in the Auditory Forebrain {#ar23907-sec-0025}
----------------------------------------------------------

Historically, studies of brain structure and function have emphasized characterization of neurons and neuronal networks, but interest in the roles of glia has rapidly increased (Kettenmann and Ransom, [2013](#ar23907-bib-0118){ref-type="ref"}). In part, this stems from evidence that glial and neuro‐glial interactions are involved in a vast array of brain functions, such as regulation of synaptic transmission, plasticity, information processing, myelination, neuronal development, and response to injury. Several outstanding reviews cover various aspects of this rapidly growing field (Stevens et al., [2002](#ar23907-bib-0183){ref-type="ref"}; Fields and Burnstock, [2006](#ar23907-bib-0075){ref-type="ref"}; Boison, [2008a](#ar23907-bib-0029){ref-type="ref"}; Pelligrino et al., [2011](#ar23907-bib-0161){ref-type="ref"}; Lovatt et al., [2012](#ar23907-bib-0135){ref-type="ref"}; Del Puerto et al., [2013](#ar23907-bib-0065){ref-type="ref"}; Domercq et al., [2013](#ar23907-bib-0067){ref-type="ref"}; Boison and Aronica, [2015](#ar23907-bib-0032){ref-type="ref"}; Bynoe et al., [2015](#ar23907-bib-0040){ref-type="ref"}; Coppi et al., [2015](#ar23907-bib-0051){ref-type="ref"}; Croft et al., [2015](#ar23907-bib-0056){ref-type="ref"}; Koles et al., [2016](#ar23907-bib-0128){ref-type="ref"}). The various roles played by glia often involve bidirectional signaling between neurons and glia, or between glia (Parpura and Zorec, [2010](#ar23907-bib-0158){ref-type="ref"}; Araque et al., [2014](#ar23907-bib-0009){ref-type="ref"}; Perea et al., [2014](#ar23907-bib-0162){ref-type="ref"}; Croft et al., [2015](#ar23907-bib-0056){ref-type="ref"}). *Astrocytes*, in particular, can detect synaptic activity *via* ionotropic and metabotropic receptors, initiating changes in signaling that modulate synaptic transmission and plasticity (Ota et al., [2013](#ar23907-bib-0156){ref-type="ref"}; Bernardinelli et al., [2014](#ar23907-bib-0021){ref-type="ref"}; Chung et al., [2015](#ar23907-bib-0048){ref-type="ref"}; De Pitta et al., [2016](#ar23907-bib-0063){ref-type="ref"}). For example, Ca^2+^ signaling in astrocytes can be invoked by sensory stimulation (Wang et al., [2006](#ar23907-bib-0204){ref-type="ref"}; Winship et al., [2007](#ar23907-bib-0214){ref-type="ref"}), initiating the vesicular exocytosis of "gliotransmitters" (e.g., glutamate, ATP, adenosine, peptides) that modulate the activity of neurons and other glia. *Oligodendrocytes* are responsible for myelination during development, but even in mature cells, activity‐dependent changes in myelin production may contribute to the regulation of critical periods for plasticity in sensory systems (Takesian and Hensch, [2013](#ar23907-bib-0187){ref-type="ref"}). Some of these interactions are mediated by neurotransmitter receptors localized on oligodendrocytes (Garcia‐Barcina and Matute, [1996](#ar23907-bib-0089){ref-type="ref"}; Karadottir et al., [2005](#ar23907-bib-0116){ref-type="ref"}; Micu et al., [2007](#ar23907-bib-0145){ref-type="ref"}; Bagayogo and Dreyfus, [2009](#ar23907-bib-0012){ref-type="ref"}), paired with release mechanisms that permit signaling back to neurons (Fruhbeis et al., [2013](#ar23907-bib-0087){ref-type="ref"}). *Microglia* are activated in response to traumatic injury to the brain, but in healthy tissue (not activated), their processes move about in the neuropil, surveying local conditions (Wake et al., [2013](#ar23907-bib-0201){ref-type="ref"}). Like astrocytes, microglia make contacts with synapses, with effects on structure and function (Wake et al., [2009](#ar23907-bib-0200){ref-type="ref"}; Tremblay et al., [2010](#ar23907-bib-0192){ref-type="ref"}), neuronal activity (Moriguchi et al., [2003](#ar23907-bib-0147){ref-type="ref"}; Hayashi et al., [2006](#ar23907-bib-0101){ref-type="ref"}), synaptic plasticity and learning (Tremblay and Majewska, [2011](#ar23907-bib-0191){ref-type="ref"}; Tremblay et al., [2012](#ar23907-bib-0193){ref-type="ref"}), and many other functions (Kettenmann et al., [2013](#ar23907-bib-0120){ref-type="ref"}; Morris et al., [2013](#ar23907-bib-0148){ref-type="ref"}). These interactions are achieved, in part, through the expression of many types of neurotransmitter receptors in several families (Pocock and Kettenmann, [2007](#ar23907-bib-0163){ref-type="ref"}; Kettenmann et al., [2011](#ar23907-bib-0119){ref-type="ref"}; Gertig and Hanisch, [2014](#ar23907-bib-0091){ref-type="ref"}).

Among the signaling pathways identified, purinergic signaling is a widespread mechanism for communication between neurons, glia, and vascular cells in the brain (Burnstock and Knight, [2004](#ar23907-bib-0037){ref-type="ref"}; Fields and Burnstock, [2006](#ar23907-bib-0075){ref-type="ref"}; Burnstock et al., [2011](#ar23907-bib-0038){ref-type="ref"}). Both ATP and adenosine can function as signals in these interactions, subserving key roles in development, behavior, regeneration, plasticity, and pathology (Stevens et al., [2002](#ar23907-bib-0183){ref-type="ref"}; Dale, [2008](#ar23907-bib-0061){ref-type="ref"}; Boison et al., [2010](#ar23907-bib-0033){ref-type="ref"}; Burnstock et al., [2011](#ar23907-bib-0038){ref-type="ref"}; Wei et al., [2011](#ar23907-bib-0207){ref-type="ref"}; Zimmermann, [2011](#ar23907-bib-0224){ref-type="ref"}; Krugel, [2016](#ar23907-bib-0129){ref-type="ref"}; Pedata et al., [2016](#ar23907-bib-0160){ref-type="ref"}). Astrocytes (and neurons) release ATP, which is converted to adenosine in the extracellular space, with impacts on both neurons and glia (Pascual et al., [2005](#ar23907-bib-0159){ref-type="ref"}; Lovatt et al., [2012](#ar23907-bib-0135){ref-type="ref"}). A major role of A~1~Rs in astrocytes is to trigger the removal of excess adenosine from the synapse *via* ENTs (Boison, [2008b](#ar23907-bib-0030){ref-type="ref"}; Lovatt et al., [2012](#ar23907-bib-0135){ref-type="ref"}; Hines and Haydon, [2014](#ar23907-bib-0102){ref-type="ref"}), with effects on glutamatergic transmission (Masino et al., [2002](#ar23907-bib-0140){ref-type="ref"}) and plasticity (Navarrete et al., [2012](#ar23907-bib-0150){ref-type="ref"}). A~1~R signaling can also mediate protective effects on astrocytes during insults such as hypoxia (Ciccarelli et al., [2007](#ar23907-bib-0049){ref-type="ref"}; Bjorklund et al., [2008](#ar23907-bib-0022){ref-type="ref"}). In oligodendrocytes, A~1~Rs promote myelination during axonal maturation (Stevens et al., [2002](#ar23907-bib-0183){ref-type="ref"}), and contribute to white matter loss in pathology (Kim et al., [2005](#ar23907-bib-0122){ref-type="ref"}). In microglia, A~1~R activation on microglia can regulate proliferation (Haselkorn et al., [2010](#ar23907-bib-0100){ref-type="ref"}), limit the inflammatory response (Tsutsui et al., [2004](#ar23907-bib-0194){ref-type="ref"}), contribute to the neuroprotective effects associated with adenosine delivery (Lauro et al., [2010](#ar23907-bib-0131){ref-type="ref"}; Pedata et al., [2016](#ar23907-bib-0160){ref-type="ref"}), and modulate short‐term synaptic transmission and plasticity (George et al., [2016](#ar23907-bib-0090){ref-type="ref"}). Many other functions are mediated by purinergic signaling through other receptors and pathways, as well.

A general finding of this study was that *Adora1* is expressed by subpopulations of all three glial classes in A1 and MG (Fig. [20](#ar23907-fig-0020){ref-type="fig"}). Astrocytes and oligodendrocytes were more likely to express *Adora1* ^*+*^ puncta than microglia. Transcript abundance was much lower in glia than neurons, regardless of location, and was uniform across cortical layers in A1 or between divisions in MG (except perivascular and pial astrocytes, where *Adora1* expression was usually nominal). This pattern contrasts sharply with relatively strong *Adora1* expression by the majority of neurons.

The reasons for the differences between neurons and glia are not entirely clear, but presumably related to the specific functions mediated by A~1~Rs in each cell type. Certainly, expression levels in glia are sufficient to meet functional demands, and the uniformly low transcript abundance suggests that those needs do not fluctuate widely over time or location. That is, high receptor numbers are not necessary to maintain functionality, in general, nor are high numbers needed to achieve a specialized function that might require elevated sensitivity.

For other functions, A~1~R‐adenosine signaling in glia may not be as important as those mediated by other purine receptors (Fields and Burnstock, [2006](#ar23907-bib-0075){ref-type="ref"}), several of which are significantly expressed in A1 and MG (Fig. [1](#ar23907-fig-0001){ref-type="fig"}). As one example, the P~2~ ATP receptor, *P2ry12*, is highly expressed in microglia compared to neurons and other glia (Zhang et al., [2014](#ar23907-bib-0221){ref-type="ref"}; Zeisel et al., [2015](#ar23907-bib-0217){ref-type="ref"}), with specialized roles in the response to local brain injury (Davalos et al., [2005](#ar23907-bib-0062){ref-type="ref"}; Amadio et al., [2006](#ar23907-bib-0004){ref-type="ref"}). Much remains to be learned about purinergic signaling, in general, as this receptor family may contribute to neuron--glia interactions, and many other functions in auditory forebrain.

4.6. Subcellular Localization of Transcripts {#ar23907-sec-0026}
--------------------------------------------

Transcripts for the seven mRNA markers used in this study were primarily concentrated in the somatic cytoplasm, but for some markers (*MBP, Aqp4, Adora1*), labeled puncta were consistently found in the neuropil. DIC microscopy indicated that most were localized to peripheral processes. High numbers of *MBP* ^*+*^ transcripts were located in the peripheral processes of oligodendrocytes (presumably), consistent with numerous previous studies in other brain regions (Colman et al., [1982](#ar23907-bib-0050){ref-type="ref"}; Trapp et al., [1987](#ar23907-bib-0190){ref-type="ref"}; Verity and Campagnoni, [1988](#ar23907-bib-0197){ref-type="ref"}; Shiota et al., [1989](#ar23907-bib-0180){ref-type="ref"}; Barbarese et al., [1995](#ar23907-bib-0016){ref-type="ref"}; Ainger et al., [1997](#ar23907-bib-0002){ref-type="ref"}; Muller et al., [2013](#ar23907-bib-0149){ref-type="ref"}). Although some instances of labeled puncta were possibly nonspecific labeling (noise), the majority was localized to peripheral processes. Internal evidence for this conclusion derives from the high specificity of the probes, and the low levels of noise in areas with few cells (e.g., cortical layer 1).

In addition, it is well established that the transcripts of perhaps thousands of protein coding genes are localized in the neuropil, where local translation may occur (Steward and Levy, [1982](#ar23907-bib-0184){ref-type="ref"}; Tiruchinapalli et al., [2003](#ar23907-bib-0189){ref-type="ref"}; Bockers et al., [2004](#ar23907-bib-0027){ref-type="ref"}; Poon et al., [2006](#ar23907-bib-0164){ref-type="ref"}; Zhong et al., [2006](#ar23907-bib-0222){ref-type="ref"}; Lein et al., [2007](#ar23907-bib-0133){ref-type="ref"}; Giuditta et al., [2008](#ar23907-bib-0093){ref-type="ref"}; Cajigas et al., [2012](#ar23907-bib-0042){ref-type="ref"}; Sakers et al., [2017](#ar23907-bib-0173){ref-type="ref"}). Among the genes with significant neuropil expression in hippocampus are *Adora1*, *MBP*, *Aqp4*, *VGluT1*, and numerous neurotransmitter receptors (Cajigas et al., [2012](#ar23907-bib-0042){ref-type="ref"}). In a recent study focused on astrocytes, Sakers et al. ([2017](#ar23907-bib-0173){ref-type="ref"}) showed that the machinery for local translation of transcripts is localized in their peripheral processes. RNAseq analyses of peripheral astrocyte fractions revealed modest levels of *Adora1*, *Aqp4*, and *GFAP*, suggesting some degree of transcript expression outside somata. This could be functionally significant, as a single astrocyte may contact thousands of synapses (Oberheim et al., [2006](#ar23907-bib-0152){ref-type="ref"}), and numerous functions may benefit from local translation. Altogether, these findings are consistent with present observations in the auditory forebrain, and suggest that peripheral transcript localization is a general property of some genes.

4.7. Transcript Abundance {#ar23907-sec-0027}
-------------------------

Relevant to the subject of transcript localization is the relationship between transcript and protein abundance. Within a cellular compartment, such as the somatic cytoplasm or peripheral process, how many transcripts constitute a functionally significant number? For somata, we took a conservative approach in setting the threshold to three or more copies. This threshold was somewhat arbitrary, and may under‐ or over‐represent cells that in fact produce significant amounts of functional protein. Moreover, our approach excluded transcripts located beyond somata within peripheral processes. Indeed, the presence of single transport granules containing mRNA (along with ribosome and other molecules) appears to be sufficient for local translation in the peripheral processes of oligodendrocytes (e.g., myelin basic protein) (Muller et al., [2013](#ar23907-bib-0149){ref-type="ref"}).

Unfortunately, correlations between transcript and protein abundance are variable, and tend to be modest on average (Ghazalpour et al., [2011](#ar23907-bib-0092){ref-type="ref"}; Vogel and Marcotte, [2012](#ar23907-bib-0199){ref-type="ref"}). Factors contributing to the variability include regulation of transcription and translation, transcript stability, and protein degradation, as well as methodological limitations. Thus, the relationship between transcript copy number in the cytoplasm and protein expression levels in the cytoplasm or elsewhere in the cell is not clear for a given target. As mentioned above, the relationship between transcripts and translated proteins may be further complicated in neurons for which transcripts are concentration in somatic cytoplasm, but the proteins are expressed in a different subcellular compartment, such as axon terminals. This is the case for VGluT1, VGluT2, and VGAT (Hackett et al., [2016](#ar23907-bib-0099){ref-type="ref"}), as well as A~1~Rs.

4.8. Summary {#ar23907-sec-0028}
------------

The findings of this study are summarized in Figure [20](#ar23907-fig-0020){ref-type="fig"}. The main findings for neurons were that *Adora1* mRNA is strongly expressed by the majority of glutamatergic neurons in layers 3--6 of A1 and all divisions of the MG, compared to modest expression by subpopulations of GABAergic neurons in A1. A~1~R immunoreactivity was also found across layers, but peak expression corresponded with bands of elevated VGluT2 expression in L3/L4 and L6. These patterns indicate that A~1~Rs are likely co‐expressed with VGluT1 or VGluT2 in axon terminals of respective glutamatergic projections. For glia, *Adora1* mRNA is expressed by subpopulations of all three glial subtypes in L3--L6 of A1 and all divisions of MG, but transcript abundance is low compared to neurons.

The widespread *Adora1* expression by MG neurons implies that the presynaptic modulation of glutamate release by adenosine may be a general property of all MG projections to auditory cortex, and therefore potentially impact excitatory neurotransmission and plasticity in all areas of auditory cortex. As A~1~R functionality in auditory cortical neurons appears to be distinct from MG neurons, focused studies will be needed to uncover the roles of pre‐ and postsynaptic receptors in the networks of corticocortical (CC), corticothalamic (CT), and corticotectal (Ct) projections. The expression of *Adora1* by glial subpopulations is consistent with recognized roles in development, behavior, regeneration, plasticity, and pathology, but specific roles in the auditory forebrain are unknown.

An added application of the data from this study concerns the targeting of specific cell types for future functional studies, as the properties of A~1~R‐adenosine signaling in the auditory forebrain are currently limited to a subset of the TC projections from MGv to L4 of A1. Gene editing, transgenic, optogenetic, and pharmacologic manipulations of A~1~R‐mediated signaling would be expected to differentially impact subpopulations of neurons and glia in A1 and MG. Strategies to target *Adora1* or A~1~Rs in specific cell populations for experimental study of function can be developed from the data generated here.
